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 For several decades, significant scientific interest has been dedicated to developing bioactive 
small molecules to treat pathogenic infections. Despite the huge amount of efforts in the past few 
decades, resistant strains continue to emerge with every introduction of new therapeutic 
compounds into the clinic, leading to multi-drug resistant (MDR) strains that continue to be a 
serious health problem. This implies an urgent need for novel antimicrobial drugs to be added to 
the plethora of the already existing ones to overcome resistance. Recent studies have depicted that 
the major contributing source of the antimicrobial compound library originates from natural 
products.1 Thus, research on their biosynthesis to understand their function is of the utmost 
importance to utilize nature’s tools to generate these bioactive small molecule variants. 
Bioactive natural products, the molecules produced by living organisms, which possess 
antibacterial, antiviral, antimalarial, cytotoxic, and/or immunosuppressive properties represent a 
plentiful source of medically relevant compounds. Despite the abundance of these molecules, their 
synthesis often involves major challenges due to their complex structures. However, nature has 
overcome several major problems that we encounter during the chemical synthesis of small 
molecules. For example, enzymes that act as biocatalysts by specifically binding and orienting 
small ligands for selective modifications have provided a solution for the challenging 
stereochemical and regioselective modifications on the starting material to produce a single 
product. For the past few decades, there has been an increasing interest and demand to utilize 
enzymes as an alternative method for the production of a variety of compounds for 
chemoenzymatic semi-synthesis. The high activity of enzymes under mild conditions and the 
absence of harsh chemicals and byproducts used in chemical synthesis further emboldens this 
approach. 
Enzymes can be utilized to avoid the expensive and time-consuming route of organic synthesis 
to produce bioactive molecules. Hence, an understanding of the mechanistic and molecular basis 
of enzymatic reactions may allow the design of catalysts that can generate novel compounds or 
can modify the existing pool of bioactive compounds to create more potent variants. Such studies 
also provide a platform for developing and designing small drug molecules that may regulate 
various biochemical pathways. This dissertation describes efforts to understand the catalytic 
mechanism of proteins involved in the biosynthesis of the medically active natural product 
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roseoflavin (RoF) and studying the mechanism to understand the regulatory action of a small 
signaling molecule, avenolide, in avermectin production. The research projects described in this 
thesis provide a platform to approach the issue of antibiotic resistance biochemically. The research 
highlighted below focuses on natural products sourced from the different strains of the genus 
Streptomyces. 
The first part of the thesis represents the structural and biochemical characterization of a 
multifunctional enzyme, RosB, that is involved in the biosynthesis of RoF. RoF is the only known 
vitamin B2 analog, and as such has antibiotic activity against both Gram-positive and Gram-
negative bacteria. It is biosynthesized from a vitamin B2 precursor via two major intermediates. 
RosB is a multifunctional enzyme that carries out a challenging transformation of an aromatic 
methyl group to the aromatic amine group in riboflavin-5’-phosphate (FMN). Understanding the 
mechanism of this transformation is the major goal of chapter 2. In this chapter, I discuss the 
structure-based approach we have followed to identify active site variants of RosB, a single 
enzyme that shows oxidoreductase, decarboxylase, and aminotransferase activity, and some of 
these variants stall the reaction at various points along the reaction coordinate. These structural 
studies allowed for an investigation into a plausible route for reaction progression and provide a 
molecular rationale for the mechanism of this unusual biocatalyst. 
In chapter 3, I discuss the binding of avenolide, a unique class of small signaling molecule that 
autoregulates the production of antibiotic avermectin in the industrial microorganism S. avermitilis 
through structural and biochemical characterization. My work in this chapter identified the new 
structural features of avenolide binding to its cognate receptor AvaR1 and antagonism of DNA 
binding by AvaR1 by the small molecule ligand. These studies also opened new opportunities to 
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CHAPTER 1: Introduction 
 
 The improvement of human health has been a major focus of academic and industrial research 
in the field of medicinal chemistry. There has been tremendous demand and an ever-growing 
interest by pharmaceutical companies to highlight human medical needs. Microorganisms have 
likely played an important role in human health, both positively, through mutualistic host-microbe 
interactions, and negatively, as disease-causing agents. These disease-causing microorganisms, or 
pathogens, have led to tremendous loss of human life and suffering throughout recorded history as 
has been well-documented in episodes such as the Black Death epidemic. 
Pathogens affect humans through extremely diverse mechanisms and affect a broad range of 
tissues. Over the past few centuries, diseases including leprosy, tuberculosis, and the plague, 
among other epidemic infections, have been caused by specific pathogenic microorganisms.2,3 
Medicinal chemists have developed multiple tools to fight against these infectious pathogens. The 
first was the development and use of vaccines that are specifically designed to train the host’s 
immune system to recognize and neutralize a harmful pathogen. After the development of the first 
vaccine in 1796 for smallpox, several vaccines have been successfully marketed and utilized by 
the public to prevent other infectious diseases.4  
The second tool-set is the application of antibiotics to kill pathogenic bacteria upon infection. 
The term antibiotic, meaning “against life,” was coined by Selman Waksman in 1947.5 The 
discovery of penicillin by Alexander Fleming in 1928 introduced the ‘antibiotic era,’ with 
penicillin being the first isolated antibiotic molecule11. Penicillin emerged as a “magic bullet” that 
selectively targets disease-causing microbes and provided the foundation for the discovery of a 
large number of antimicrobial drugs from different classes.12 These antibiotics tend to act on 
specific targets of pathogenic bacteria through well-defined mechanisms. Examples of such 
mechanisms include either inhibition or the mis-regulation of important biochemical processes 
involved in the synthesis of the bacterial cell wall, DNA, and proteins.10 This results in either the 
inhibition of cell growth and division, with compounds which act in this way termed bacteriostatic 
antibiotics, or the killing of the bacterial cell, with compounds which act in this way termed 
bactericidal antibiotics.11In addition to bacteria, several other microbial classes have also been 
treated using antibiotics and these include fungi, viruses, and other parasites.6,7 Most existing 
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antibiotics are either the natural compounds that are biosynthesized within a living organism, 
called natural products, or are natural product derivatives.9  
A recent report by Newman and Cragg has highlighted the significance of natural products in 
drug discovery for the last four decades that have resulted in some FDA approved/marketed natural 
products.1 The majority of new drugs have been generated from natural sources, like plants or 
microbes or they have been derived from natural products. Five decades after the discovery of 
penicillin, about 80% of marketed drugs were either natural products or analogs derived from 
natural products including a vast variety of antimicrobials like antibiotics, antiparasitic, 
antimalarials, and anticancer drugs,.40,44 Prior studies have also shown that microbial natural 
products provide a huge reservoir for antibiotic discovery.52,53 The Gram-positive bacteria of genus 
Streptomyces is one such class of microbes that are of medical and industrial importance; these 
soil dwelling species are known to produce more than 70% of the commercially important natural 
products used as immunosuppressants, herbicidal, antibiotic, anticancer, anthelmintic, and 
antifungal compounds.54 What is interesting to note is that more than 150,000 antibiotics have 
been estimated to be able to be produced by Streptomycetes alone.55  
Antibiotics are among the most successful drugs used over the past 100 years, responsible not 
only for saving countless lives and enabling modern medical procedures that otherwise would be 
unthinkable.8 However, they can also lead to an increased risk of developing other infections or 
allergic responses, reducing the efficacy of other medications due to negative drug-drug 
interactions, and the development of microbial resistance against antibiotics.15 Due to their 
prolonged and extensive worldwide use, many bacteria and other infectious pathogens have 
evolved to become irresponsive to the use of the most potent antibiotics, leading to the 
ineffectiveness of standard treatments and persistent infections.16 This process gives rise to the 
burgeoning issue of anti-microbial resistance against nearly all available antibiotic molecules, 
posing an enormous medical and financial challenge.17 The World Health Organization (WHO) 
has highlighted multi-drug resistance (MDR) as a serious emerging threat to human health.18 
Recent statistical data from the Center for Disease Control and Prevention (CDC, 2017) indicates 
that more than 2 million people in the United States are infected by drug resistant bacteria and at 
least 23,000 people die because of these infectious diseases annually.13 The WHO is also 
concerned that at the current rate of antimicrobial resistance development, infections by resistant 
pathogens will become the leading cause of deaths in the US and cause approximately 10 million 
3 
 
deaths globally by the end of 2050. (Figure 1.1).19 Recent reports by the World Economic Forum 
Global Risks also list antibiotic resistance as one of the greatest threats to the economic market 
with an annual cost of roughly $1.8 billion.13 
The unavoidable rise of resistant pathogens renders current treatments less effective and 
exacerbates a major supply problem; specifically, the decline in rate at which we are developing 
new and effective tools to fight against infections.15 Efforts toward antibiotic discovery and 
development have decreased while resistance continues to propagate (Figure 2(a))21. Historically, 
the goal of finding novel antibiotics with low toxicity to kill a pathogen has been strongly hindered 
by unfavorable economics as antibiotics are prescribed only for a short duration while other drugs 
may be prescribed for much longer.22,23 In addition to the economic risks, the promiscuous use of 
antibiotics also leads to the unprecedented conditions for the mobilization of resistance elements 
in bacterial populations and spread through previously antibiotic-sensitive pathogens resulting in 
fatal outcomes.24 
A recent review by Brown and Wright highlights the prevalent models of each era of antibiotic 
development (Figure 2(b)).9 The stated timeline describes the history and future of antibiotic drug 
discovery starting with the discovery of sulfonamide and penicillin in the “golden era” which is  
often characterized by the widespread utilization of cellular screening of natural product extracts 
to identify new antibiotics. The subsequent drug development by chemical modification to these 
scaffolds in the medicinal-chemistry era was highly successful. However, efforts in the resistance 
era to find specific and new antibiotics by target-based approaches have not been successful. Thus, 
for the development of narrow spectrum antibiotics, a huge emphasis on new strategies and 
innovative methods to focus on unconventional targets is required to forestall the potential coming 
of the post-antibiotic era. 9  
While the emergence of multi-drug resistance has long been of concern, understanding of the 
remarkable diversity of the mechanisms of resistance has grown only in the past two decades. Any 
efforts put toward developing new antibacterial drugs must also focus on possible mechanisms of 
resistance as a mandatory requirement for the early stage drug development.8,25,10 In addition to 
the intrinsic resistance of certain bacterial strains against a class of antibiotics, another major risk 
is acquired resistance in otherwise susceptible bacteria. This acquired resistance arises in a 
resistant population of bacteria via mutations in genetic elements and propagates through initially 
susceptible bacteria through horizontal gene transfer. Bacterial adaptive resistance has been 
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observed in response to even the most potent antibiotics, resulting in the evolution of methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).26  
Advances have been made that better our understanding of the mechanisms and chemistry of 
both the action of and the resistance to antibiotics.13,17 These studies also highlight plausible  
mechanisms of resistance and their implementation in developing the needed new antibiotics. The 
innate resistance in microorganisms, that is the frontline defense against antimicrobials, comes 
from organisms producing their own antimicrobials as a defense against other pathogens It can 
also develop due to the restricted penetration of several antibiotics to the protected pathogenic 
bacterial envelope.  Slight modifications in the structural features of the bacterial cell wall in some 
strains of pathogenic bacteria also contribute to innate resistance. For example, the pathogen 
Pseudomonas aeruginosa can generate biofilms composed of polysaccharide matrices inhibiting 
access to antibiotics.27 
 Acquired resistance can be mediated by several mechanisms that fall into five categories: 
overexpression of efflux pumps, enzymatic degradation of active drug, enzymatic covalent 
modification of target or active compound and transcriptional up-regulation of the target (Figure 
1.2(c)). The first category includes the overexpression of efflux pumps to prevent accumulation of 
antibiotic inside the cells. Bacterial efflux pumps actively transport the antibacterial agents out of 
the cell before it can reach its target site and exert its effect.28 The resulting decrease in intracellular 
concentrations due to efflux of antibiotics from within the cells of the target pathogens results in 
an effective loss of activity. This process significantly contributes to the intrinsic resistance of 
Gram-negative bacteria against several drugs that have been used to treat infections caused by 
Gram-positive bacteria.29 There are numerous examples of MDR efflux pumps that carry the 
potential to transport a wide range of structurally and functionally dissimilar substrates. Hence, 
there is a need to understand the molecular basis for the upregulation of efflux pumps as a 
mechanism of defense.30,31  
Microorganisms may also acquire resistance by enzymatic covalent modifications of either the 
drug itself or its target. The antibiotic target within the target cells may be altered by random 
mutations in target genes resulting in effective desensitization of the antimicrobial target. These 
structural modulations in key binding elements in targets prevent efficient antibiotic binding.8 For 
example, S. pneumoniae and S. aureus are reported to select for resistance against linezolid, a 
member of the oxazolidinone class of antibiotics, by mutations in the genes encoding its target, 
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the 23S rRNA.32,33 Therefore, even a single point mutation in the genes encoding an antibiotic 
target can lead to resistance which can be propagated to the large and diverse population of 
pathogens. Binding of an antibiotic to its specific target can also be hampered by enzymatic 
transfer of chemical groups like aryls, phosphates, or nucleotides to vulnerable sites on the 
antibiotic molecules. 
The third mechanism of resistance is enzymatic degradation of antibiotic compounds. Due to 
the major prevalence of enzyme catalyzed degradation of antibiotics since 1940, various sub 
classes of degradative enzymes have been identified within pathogens that render the antibiotics 
ineffective by chemical modifications.34 These transformations include hydrolysis, oxidation, or 
non-hydrolytic elimination.35 For example, the β-lactam antibiotics, such as penicillins, 
carbapenems, and monobactams, are hydrolyzed by a diverse range of β-lactamases.36,37,38 Thus, 
normally susceptible populations of bacteria may become resistant to antimicrobial agents through 
mutation and selection or by acquiring from other bacteria the genetic information that encodes 
these degradative enzymes. 
Broad-spectrum antibiotics harm not only pathogens but also beneficial bacteria, resulting in 
the faster development of antibiotic resistance. The obvious but difficult solution to this problem 
is to develop narrow spectrum antibiotics that target specific pathogens. Some antibacterial natural 
products display a narrow spectrum of bioactivity by employing the strategies that are used to trick 
target bacteria into the active transport of the drug into the cells. However, these systems display 
no therapeutic applications and their complex structure, composition, and a limited number of 
derivatives highlight their drawbacks as non-natural systems and points out the importance of 
naturally occurring molecules.  
The major challenge then becomes how to access the vast library of natural product antibiotics 
from Streptomycytes which remain inaccessible due to silent gene clusters regulated via unknown 
mechanisms. Studies have shown that the production of antibiotics is regulated by various bacterial 
hormones or small signaling molecules that mediate the process by binding to their cognate 
receptors. One such receptor is AvaR1, that belongs to the TetR super family of transcriptional 
repressors. These proteins regulate genes whose products are involved in multidrug resistance, 
various catabolic pathways, biosynthesis of antibiotics, responses to osmotic stress, and 
pathogenicity of gram-negative and gram-positive bacteria.56 The homologous transcriptional 
repressors of this family are divided into three main classes.  The largest and most studied of these 
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is the -butyrolactone (GBL) receptors which are named after their cognate ligands, -
butyrolactones. GBLs are small microbial signaling molecules, or hormones, that bind to these 
receptors, thus changing the receptor’s affinity for the binding of DNA and, by extension, 
regulating the production of secondary metabolites. 57 All members of this repressor family are 
shown to suppress secondary metabolism. Binding of these repressors with a threshold 
concentration of their cognate ligands through ligand binding domain regulates transcription 
repression. Because of this binding interaction, the repressor is released from DNA, resulting in 
derepression of downstream genes involved in the biosynthesis of antibiotic molecules.58,59,60 
        The largest group of these signaling molecules is the -butyrolactone (GBL) derivatives, 
whose 14 identified members share a 2,3-disubstituted-GBL scaffold but differ in regard to 
stereochemistry, chain length, and branching of C2 fatty acid side chains.
60 The newest class of 
these autoregulators are the butenolide signaling molecules that bind to their corresponding 
butenolide receptors. While they have structural similarity with GBLs, butenolides contain a 
different cyclized head group.49 Though there is currently only one butenolide receptor with its 
characterized cognate ligand, it has gained significant interest because it has been shown to be 
essential for regulating avermectin production in Streptomyces avermitilis.61 This small molecule 
autoregulator drew our attention also because a semi-synthetic analog of avermectin, ivermectin, 
shared the 2015 Nobel Prize for Physiology or Medicine.62  
In contrast to the prevalence of natural product and natural product derivatives as new drugs, 
the decline of pharmaceutical industrial research on natural products has been the major hurdle in 
bringing a natural product-based small molecule into the market. Despite being a period in which 
the expansion of synthetic chemistry caused pharmaceutical companies to cut back on their 
utilization of natural products in drug discovery, there are many promising drug candidates in the 
current development pipeline that are of natural origin..44  Additionally, much of nature’s vast 
array of small molecules still remains unexplored and the chemical diversity provides 
opportunities for  the further developments in the discovery of novel core scaffolds to generate 
chemical libraries based on natural products in drug discovery. 
      In parallel to the need to study natural product biosynthesis for the improvement of human 
health, such enzymes also have other practical purposes and, along with the advent of utilizing 
organic synthesis as a critical component to producing useful and bioactive small and complex 
molecules, purified enzymes or in vivo production systems also have drawn extensive interest in 
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their use as bio catalysts.45 Enzymes have been shown to have applications in producing a wide 
variety of chemicals used in day to day life by their extensive use as industrial catalysts alongside 
traditional chemical methods.46 All of these applications can be attributed to the unique features 
enzymes possess over traditional organic synthesis. For example, enzymes interact with their 
cognate substrates with stringent regioselectivity and stereospecificity, resulting in highly specific 
and stereochemically pure products. Therefore, the use of enzymes as biocatalysts not only avoids 
the selectivity concerns associated with organic syntheses, but also helps by surpassing multiple 
deprotection/protection steps to achieve stereospecificity without compromising yield.  
Another advantage of using enzymes over organic synthetic methods is that they can be used 
in environmentally friendly conditions, avoiding toxic chemicals, solvents, heavy metals, and 
harsh temperatures or pH conditions.47 To enable the efficient and complete use of enzymes as 
synthetic tools, it is critical to effectively elucidate their mechanisms of action. An enormous 
amount of research and recent technological developments in this area provide a platform to find 
new and unusual activities of a vast number of uncharacterized enzymes. Chemical and structural 
diversity of naturally-isolated compounds and genomics suggest the role of enzyme catalysis in 
the many interesting transformations found in secondary metabolites and natural products. Natural 
compounds often contain unusual chemical functional groups that are not detected in primary 
metabolism that include unusual C-N bond formation, epoxidation, cyclizations, etc.  
The research described in this dissertation highlights my efforts to structurally characterize 
enzymes with unusual activities and understand their mechanisms of catalysis. These enzymes are 
involved in either natural product biosynthesis or in the regulation of various biosynthetic 
pathways. In order to progress the field in the aforementioned directions and areas, two major 
pursuits are described in this dissertation: a structure-based investigation into the nature of RosB, 
a multifunctional enzyme involved in roseoflavin (RoF) biosynthesis and also structural studies of 
AvaR1, the first characterized butanolide receptor.48,49 RosB is a unique enzyme that functions as 
three different enzymes to catalyze a challenging transformation in RoF biosynthesis, and  AvaR1 
is a member of a TetR super family of transcriptional repressors that are homologous to 
butyrolactone receptors.a more well-known class of homologous proteins found throughout 
streptomycetes..   
 Roseoflavin (8-dimethylamino-8-demethyl-D-ribloflavin, RoF), produced by Streptomyces 
devawansis, is the only known natural vitamin B2 (riboflavin) analog with antibiotic activity and 
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antivitamin B2 activity against both Gram-negative and Gram-positive bacteria. Biosynthesis of 
RoF has been described to involve two distinctive enzymes, RosA and RosB. RosB catalyzes the 
formation of 8-aminoriboflavin-5’-phosphate (AFP), the key intermediate in roseoflavin 
biosynthesis, from the metabolic precursors riboflavin-5’-phosphate (RP, also known as FMN) 
and glutamate.50,51 RosB plays the role of an oxidoreductase, decarboxylase, and aminotransferase 
in the biosynthesis of RoF. The work described in chapter 2 was aimed at understanding how RosB 
catalyzes this transformation in RoF biosynthesis. In order to gain insights into the mechanism for 
this chemically challenging transformation, I utilized a structure-based approach to identify active 
site variants of RosB that stall the reaction at various points along the reaction coordinate. Crystal 
structures of individual variants in complex with different reaction intermediates, identified via 
mass spectroscopic analysis, illuminate conformational changes that occur at the active site during 
multi-step conversion. These studies provide a plausible route for the reaction progression and 
provide a molecular rationale for the mechanism of this unusual biocatalyst. 
The work described in chapter 3 is focused on understanding the regulatory mechanism of 
avenolide for the production of avermectin in S. avermitilis. The work highlights my efforts to 
develop a total synthetic route for avenolide production and understand the mechanism of 
avenolide mediated regulation of avermectin production. According to the studies reported by 
Kitani et al. some candidate genes have been shown to be responsible for installing different 
functionalities into the avenolide structure, but complete biosynthesis is not fully understood. 
Through various bioinformatic analyses, similar gene arrangements have also been found in other 
species of the genus Streptomyces, offering the possibility that work in understanding the S. 
avermitilis system could be applied to more species. This leads to our hypothesis that AvaR1 is a 
model for the regulation of secondary metabolites in other streptomyces.  In chapter 3, I describe 
the crystal structures of AvaR1 alone and bound to either avenolide or small double stranded DNA 
fragments. Biochemical studies carried out with synthesized avenolide, synthesized in 24 steps, 
also correlate well with the structural data obtained. Therefore, a deeper understanding of structural 
and biochemical studies would provide more insight into the genetic understanding of the 















Figure 1.2: (a) Decreased rate of antibiotic approval in the past few decades; (b)  Models of drug 
discovery and development throughout time 9; (c) Antibiotic resistance strategies in bacteria. 


























Figure 1.3: Newman and Craggs’s analysis for the contribution of natural resources in the drug 






















CHAPTER 2: Structure Guided Analysis of a Key Enzyme Involved in the 
Biosynthesis of an Antivitamin 
Introduction* 
Vitamins are essential for growth, development and cellular maintenance of multicellular 
organisms. Consequently, vitamin analogues can act as anti-metabolites and can stop cell growth 
and survival, providing a promising strategy for the development of novel antimicrobial 
compounds.1 Dedicated vitamin transporters can mediate efficient uptake of such vitamin 
analogues, providing an expedient route for entry into target cells. As these analogues may engage 
multiple cellular targets, antivitamins are promising lead candidates for antimicrobial 
development.2,3 Hence, antivitamins add to the arsenal of new therapeutics to provide potential 
solutions to the burgeoning problem of multi-drug resistance.    
Roseoflavin (8-dimethylamino-8-demethyl-D-ribloflavin, RoF), a metabolite biosynthesized 
by Streptomyces davawensis and Streptomyces cinnabarinus, is the only known natural vitamin 
B2 (riboflavin) analog with antibiotic activity against both Gram-negative and Gram-positive 
bacteria.4, 5 Metabolic products of RoF negatively affect the riboflavin biosynthetic and export 
machinery by inhibiting target flavoenzymes that regulate riboflavin production in bacteria.6,7,8 
The biosynthetic pathways towards RoF had remained elusive for several years despite the known 
role of riboflavin as precursor.4,9 Feeding studies in S. davawensis demonstrated that the 
biosynthesis of RoF from riboflavin occurs via the intermediacy of 8-amino- (AF) and 8-
methylamino-8-demethyl-D-riboflavin (MAF).4 Cell-free extracts from S. davawensis could 
catalyze the S-adenosylmethionine (SAM)-dependent conversion of AF to MAF and RoF, 
facilitating the identification and purification of the corresponding N,N-8-amino-8-demethyl-D-
riboflavin dimethyltransferase (RosA)10 whose structure has recently been reported.11 Deletion 
analysis confirmed the role of the corresponding open reading frame, subsequently renamed rosA, 
as an essential gene in roseoflavin biosynthesis.12 However, none of the other remaining genes in 
the operon were found to be involved in RoF production, raising questions regarding the 
biosynthetic origin of AF. 
Screening of cosmid libraries from S. davawensis identified a genomic fragment that facilitated 
production of RoF in a heterologous host.12 Systematic deletion analysis within  
*This chapter has been adapted from the recent manuscript published in journal Biochemistry. 
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 the cosmid demonstrated that deletion of a single gene (termed rosB) completely abolished RoF 
production.13 Recombinant RosB (29 kDa, 257 residues) co-purified with metabolite identified as 
the phosphorylated form of AF, suggesting that riboflavin-5’-phosphate (i.e. FMN), rather than 
riboflavin, is the precursor for RoF. Biochemical studies with recombinant RosB identified the 
intermediate 8-formyl-RP (RP-CHO), which may be oxidized to the acid 8-carboxy-RP (RP-
COOH).13, 14 Addition of the amine donor L-glutamate completes the transformation to AFP. 
Hence, a single enzyme catalyzes this multi-step reaction involving an oxidative cascade, a 
decarboxylation, and a transamination step (Figure 2.1 (b)). 
The crystal structure of S. davawensis RosB revealed a classic flavodoxin-type fold with a 
unique C-terminal extension that mediates inter-subunit contacts.15 The structure also shows a 
bound ligand, presumably AFP that co-purified during preparation recombinant protein for 
crystallization. The homotetrameric assembly is likely the catalytically obligate form, as the active 
site is composed of residues from each of the four subunits. Mutations at residues that engage the 
bound ligand resulted in a loss of RosB activity but these variants were not characterized further.15 
Here, we use a structure-guided approach to clarify the roles of several active site residues in 
RosB that are implicated in catalysis. Some of these variants stall the reaction at various points 
along the aforementioned mechanistic pathway. Mass spectrometric analysis of these variant 
enzymes identifies different bound intermediates, and structural characterization of the variants 
divulge the conformational movements of an active site loop located near the vicinity of each 
intermediate. The biocatalytic utility of RosB is highlighted by its function of site-specific 
substitution of methyl groups on polyaromatic compounds, and our structure-guided studies may 







Riboflavin-5’-phosphate and other chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO). Oligonucleotides were purchased from Integrated DNA Technology (IDT). 
 
Cloning and Overexpression of recombinant RosB from E.coli.  
Steptomyces dewavansis strain (BN159_7989) was purchased from Japanese Collection 
Microorganism (JCM4913). Genomic DNA was isolated using Qiagen-gDNA purification 
protocol and was used as a template to amplify rosB using the PCR with forward and reverse 
primers designed based on the known sequence (Table 2.1). These primers were designed 
containing the ligation-independent cloning (LIC) v1 tags specific for the pET His6 tobacco etch 
virus (TEV) protease LIC cloning vector (2B-T) (Addgene plasmid #29666). T4 ligase treated 
PCR amplified product was ligated with Ssp-I linearized and T4 treated vector using LIC cloning 
protocol provided by Addgene, to construct an N-terminal His6-TEV tagged protein expression 
plasmid. The resultant product was transformed into Escherichia coli DH5α and plasmids isolated 
from individual colonies were sequenced by ACGT Inc. (Wheeling, IL). E. coli Rosetta (DE3) 
competent cells were then transformed with a sequence-verified plasmid and cells were grown to 
optical density at 600 nm (OD600) of 0.5-0.6 at 37 °C and 200 rpm, in LB-containing ampicillin 
(100 μg mL−1) and chloramphenicol (25 μg mL−1). Protein production was induced with the 
addition of 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) followed by growth at 18°C 
for an additional 18-20 hours. Cells were harvested by centrifugation at 3500 rpm for 30 minutes 
and resuspended in 30 mL of buffer A (500 mM NaCl, 20 mM Tris pH 8.0 and 10 % glycerol 
(v/v)) and kept frozen at -80 oC prior to lysis. The same protocol was used for the production of 
the Y53F, Y240A and R13A RosB variants. 
 
Purification of recombinant wild-type and variant RosB  
The cells were lysed with a French press at 8,000-10,000 psi for 5 cycles. Cell debris was 
removed by centrifugation at 14000 rpm for 1h at 4 °C and cleared supernatant was loaded onto a 
5 mL HisTrap nickel-nitrilotriacetic acid (Ni-NTA) affinity column (GE Healthcare) pre-
equilibrated with 50 mL of buffer B (1 M NaCl, 20 mM Tris-HCl pH 8.0, and 30 mM imidazole). 
The column was washed with 50 mL of buffer B before eluting with a linear gradient from 0-100% 
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buffer C (1 M NaCl, 20 mM Tris-HCl pH 8.0, and 250 mM imidazole) over 30 min at 2 mL/min 
and 0.6 mbar pressure using the ÄKTApurifier™ system (GE Healthcare) at 4oC. Fractions 
containing desired protein were identified by their yellow color and confirmed by SDS-PAGE gel 
electrophoresis (~36kDa). Fractions containing pure protein (at least 90%) were combined and 
treated with Tobacco Etch Virus (TEV) protease (30 µg/mL) for about 14h at 4 °C while dialyzing 
into 300 mM NaCl, 20 mM Tris pH 8.0, 10% glycerol (v/v) and 5 mM β-mercaptoethanol (BME), 
to remove N-terminal His6 tag. Tag-free RosB was purified using a Ni-NTA column equilibrated 
with buffer A for subtractive Ni-NTA affinity chromatography. After washing the column with 30 
mL of buffer A, proteins were eluted in 5-10 mL increments using the following stepwise gradient 
of increasing buffer C: 10%, 20%, 30%, 40%, 50%, and 100%. Protein fractions at this stage 
appeared ≥ 95% pure by Coomassie-stained SDS-PAGE (Figure 2.2(a)). Samples used for 
crystallization were concentrated to ~5 mL and injected onto a 120 mL Superdex 200 10/300 GL 
column (GE Healthcare) equilibrated with a buffer composed of 300 mM KCl, 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5. UV active fractions were pooled 
and concentrated by ultrafiltration (Amicon Ultra-15, MWCO= 10kDa, Merck Millipore). Protein 
concentrations were determined by absorbance spectroscopy using Bradford standard protocol. 
The molar extinction coefficients at 280 nm and the molecular weights were estimated from the 
amino acid sequence by means of ProtParam. Purified yellow protein solution was then 
concentrated to a final protein concentration of 16 mg/mL, and was stored at -80 oC in 50 l 
aliquots. 
 
Identification of bound ligands  
To determine the identity of ligands bound to the wild-type and variant RosB, the yellow 
colored purified protein sample was denatured using a 1:1 volume ratio of 50% acetonitrile in 
water with 0.1% formic acid (FA). The precipitated protein was separated from yellow colored 
supernatant by centrifugation at 13000 rpm for 5 min at 4 oC. The supernatant was then injected 
into C18 HPLC column (250X4. 6 mm l.D and 5 m diameter) and separate peaks were collected 
using Schimadzu CBM-28A UV-Vis HPLC system. The HPLC method used for purification at 
480 nm wavelength is given in supporting table 3. Collected fractions with an absorbance of 480 
nm were characterized by electrospray ionization high-resolution mass spectrometry (ESI-HRMS; 
Waters Q-TOF Ultima ESI, UIUC).  
16 
 
Size Exclusion Chromatography  
To assess the oligomeric state of RosB, 500 l of purified protein (60 M) was injected onto 
the 200 Superdex analytical gel filtration column (10/300GL, GE healthcare) which was pre- 
equilibrated with 40 mL of gel filtration buffer (300 mM KCl, 20mM HEPES pH 7.5) with a flow 
rate of 1 mL/min. carbonic anhydrase (29 kDa), albumin (66 kDa) and alcohol dehydrogenase (150 
kDa) were used as defined protein standards. RosB eluted with a retention time between that of 
alcohol dehydrogenase (150 kDa) and albumin (66 kDa), consistent with a tetrameric assembly in 
solution. 
 
Site-directed mutagenesis  
Site directed mutagenesis was carried out using the QuikChange II XL Site-Directed 
Mutagenesis protocol according to the instructions provided by NEB. Two complementary 
mismatch oligonucleotides (forward “FP” primer and reverse “RP” primer) were used to generate 
point mutations for each mutant Y53F, R13A and Y240A using specific primers for each mutant. 
(Table 1) 
 
Crystallization, Data Collection, and Structure Determination 
Native RosB bound to AFP and other mutants Y53F, R13A and Y240A, bound to their 
corresponding ligands, were all crystallized by vapor diffusion methods using the Gryphon (Art 
Robbins Instruments (ARI), USA) robotic system and commercially available crystallization kits 
from Hampton Research and Molecular Dimensions. The crystallization conditions for the best 
diffracting crystals are given in Table 2.2. Crystals obtained in different salt and precipitant 
conditions were frozen by direct immersion into liquid nitrogen. Crystals of wild-type RosB (14 
mg/mL) in complex with AFP complex were obtained using 1.2 M succinic acid pH 7.0 at 9 oC as 
a precipitant using both sitting and hanging drop crystallization. Crystals were submerged briefly 
in the crystallization media supplemented with 25% threitol to serve as a cryoprotectant prior to 
vitrification in liquid nitrogen. Crystallographic phased were determined using anomalous 
diffraction data from crystals soaked with 1mM PCMBA for 2h at 9 oC. FMN bound crystals with 
Y53F mutant (17 mg/mL) were obtained using 60% tacsimate pH 8.0 as a precipitant and 25% 
threitol was used for cryoprotection. Efforts to produce co-crystal structures by soaking with 
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thiamine and glutamate, and efforts of obtaining crystals of the R13A and Y240A variants were 
unsuccessful.  
All diffraction data was collected at the Advanced Photon Source Sector-21 LS-CAT at 
Argonne National Labs. Indexing, scaling, and integration of diffraction data was performed using 
either the HKL-200016 or autoPROC packages.17 Heavy atom positions were determined using 
SHELX18 and crystallographic phases were calculated using SHARP19. A five-fold redundant data 
set was collected at a wavelength of 0.9756 Å. Structure determination was carried out by single 
wavelength anomalous diffraction analysis, and a single solution with 3 heavy atom sites was 
identified, and refinement of heavy atom parameters produced a figure of merit of 0.258. Initial 
models were built using the automated features in ARP/wARP, and manual rebuilt using COOT.20 
Crystallographic refinement was carried out using Refmac521 including non-crystallographic 
symmetry options. Molecular replacement (MR) was carried out using Phaser-MR (PHENIX)22 
using the RosB-AFP structure as search model. The crystallographic free R factor23 was routinely 
used to monitor progress and final models were validated using MolProbity24. Structures were 
visualized using UCSF-CHIMERA25 and PyMOL.28 
 
End-Point Analysis with wild-type and variant RosB  
The wild-type and variant proteins were incubated with excess substrate FMN (500 M), 
cofactor thiamine (0.5 mM) and co-substrate glutamate (0.5 mM) for overnight at room 
temperature in a 500L total reaction volume. A mixture with only substrate and without protein 
samples was used as negative control and a mixture without substrate was used as positive control 
for each RosB variant. Table 2.3 shows the components of various positive controls and reaction 
samples. Protein was then denatured and precipitated out using 1:1 volume ratio of 50% 
acetonitrile with 0.1% FA. Collected supernatant, after centrifugation of the precipitated protein, 
was then loaded onto C18 HPLC column (250X4.6mml.D and 5 m diameter) and peaks were 
separated using Waters Synapt G2-Si ESI/LC-MS system (Mass Spectroscopy Facility, UIUC) 







Results and Discussion 
In order to gain further insights into the roles of active site residues in the mechanism of RosB, 
we independently determined the 1.8 Å resolution crystal structure of the enzyme, crystals of 
which were intensely yellow presumably due to a bound ligand. The identity of the bound ligand 
was confirmed using high-resolution ESI mass spectroscopy, revealing a peak at 458.1059 (M+1) 
corresponding to the mass of product AFP (Figure 2.4 (a)).  
The crystal structure of AFP-bound RosB reveals the overall flavodoxin fold observed 
previously,26 wherein the homotetrameric assembly contributes residues from each subunit to 
engage the ligand that is bound at the edge of a -sheet of the N-terminus domain. The tetrameric 
nature of protein RosB bound to AFP observed in the crystal structure is also supported by the 
results obtained from the size exclusion chromatography experiments (Figure 2.3). 
The structure of wild-type RosB recapitulates the overall fold observed in other flavodoxin 
superfamily of NADH-dependent enzymes. The core structure is correlated to the rubredoxin type 
oxidoreductase (PDB ID: 1E5D).27 Despite less than 13% sequence identity, the two structures can 
be superimposed with an RMSD value of 2.0 over 150 aligned C atom (Z-score of 19.1, as 
provided via Dali server). Residues from each of the four monomers, which are all within 4 Å, 
contribute to the binding of the AFP ligand. The 3.3 Å separation between the two aromatic rings, 
Tyr240B (designating the monomer shown in brown) and isoalloxazine ring of bound AFP (from 
the monomer unit shown in blue) is suggestive of π-stacking interactions. In addition, the hydroxyl 
side chain of Tyr240B is located 3.4 Å from the N-3 of AFP, suggestive of a weak H-bond. The 
ligand is also within H-bonding distance from Tyr53P (designating the monomer shown in pink) 
(3.1 Å), and in proximity to His101P, and Glu105P. Lastly, Gln20C, and Arg13C (designating the 
monomer shown in cyan) coordinate with the phosphate group of AFP, while the main chain amide 
of and Ile91C may engage in a H-bond with a carbonyl oxygen atom of AFP (2.9 Å). 
In order to further probe the functions of these residues in catalysis, we generated site-specific 
variants of RosB. As the heterologously produced wild-type enzyme co-purified with the reaction 
product, we carried out HPLC analysis of the bound ligand for each of the variants generated in 
order to determine the extent of reaction progress. The Tyr53Phe mutation resulted in a variant 
that lacked any catalytic activity. Reverse phase HPLC analysis demonstrated that this variant co-
purified with RP, the substrate for the RosB reaction. The identity of the bound ligand was further 
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confirmed using high-resolution mass spectrometry (Figure 2.4). The above data strongly suggests 
that Tyr53 is essential for the enzymatic transformation of the aromatic methyl group of RP to the 
amine group in AFP. Possible roles for this residue in RosB may include a function as a general 
base, wherein the hydroxyl group of tyrosine could deprotonate the C8 methyl group of RP in the 
first aerobic step of the reaction. 
In order to obtain molecular details of RosB bound to its substrate, we determined the 1.96 Å 
resolution crystal structure of the Tyr53Phe RosB-RP complex. The overall structure of the 
inactive variant is similar to that of the wild-type RosB and there are not significant differences in 
the global conformations (RMSD of 0.089 for 246 C atoms aligned between the two structures). 
A superposition of wild-type RosB with the Tyr53Phe variant shows near identical alignment 
of all of the residues that are involved in interactions with the bound ligand (Figure 2.6(c)) There 
are minor differences in the orientation of the ribose moiety of the ligand but these changes are 
likely to be of consequence in catalysis. Thus, the structural data support the role of Tyr53 as the 
general base that deprotonates the C8 methyl to initiate catalysis. 
 As the Tyr53Phe variant lacked any activity, we speculated that extensive dialysis of the 
enzyme could result in dissociation of bound ligands, which would facilitate crystallization of the 
enzyme free of any bound ligands. Indeed, HPLC analysis of Tyr53Phe RosB prepared in this 
manner resulted in a loss of the yellow color and analysis showed that the enzyme lacked bound 
RP. Crystallization of apo Tyr53Phe RosB afforded the 2.0 Å resolution structure of a ligand-
free enzyme. While the overall structure was again similar to that of wild-type RosB, a 
superposition of apo Tyr53Phe RosB with the RP bound variant revealed significant changes in 
the orientation of active site residues (Figure 2.7(c)). Notable changes can be observed in the 
orientations of Arg13, and Leu109, and residue Ile91, Leu93, and Thr92 move into the cavity 
created by the loss of the bound RP ligand. 
Given the aforementioned contacts observed between the isoalloxazine ring of the ligand and 
residues Arg13, and Tyr240 of RosB, we carried out mutational analysis to affirm the importance 
of these residues. As expected, the Arg13Ala and Tyr240Phe variants showed decreased 
activity relative to the wild-type. High resolution ESI mass spectral analysis of the Arg13Ala 
variant reveals the identity of the bound ligand to be RP-CHO (Figure 2.2 (b)). This suggests a 
potential role of Arg13 in engaging the ligand phosphate in a manner that makes the C8 methyl 
group accessible enough to initiate catalysis, but doesn’t allow the reaction to proceed to 
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completion, trapping the aldehyde intermediate. Lastly, the Tyr240Ala variant was completely 
inactive and was purified as a colorless protein, unlike any of the other variants of RosB studied 
here, demonstrating further the importance of the interaction between the Tyr240 hydroxyl and N-
3 of the AFP substrate 
We next sought to verify that the bound intermediates isolated in the RosB variants were 
products of catalysis, rather than molecules serendipitously acquired from the growth media. To 
this end, we carried out in vitro end point assays with each variant in the presence of all necessary 
reactants and analyzed the accumulated products using LC-MS. We tested wild-type RosB, along 
with the Arg13Ala, Tyr53Phe, and Tyr240Ala variants by incubating each protein with 
excess FMN, glutamate and thymine pyrophosphate (Figure 2.8). 
Analysis of the wild-type RosB reaction produced a product that eluted with a retention time 
of 16.21 minutes in the LC profile, with a mass consistent with that of AFP (456.09 mass units), 
as expected. Analysis of the Tyr53Phe variant yielded a peak that eluted at 18.41 minutes, with 
a mass consistent with that of substrate FMN (455.1 mass units), consistent with a complete loss 
of catalytic activity in this variant. Notably, analysis of the Arg13Ala variant produced an eluent 
with a retention time of 16.42 minutes, and a mass consistent with that of the CHO-RP aldehyde 
(469.04 mass units). Hence, this variant produces a product that stalls, suggesting that this 
aldehyde intermediate is on pathway for the catalytic reaction. The combined data are consistent 
with the identities of the ligands observed in each variant in vivo, and are consistent with the 




Here, we have carried out a structure-function analysis of RosB, a single enzyme that shows 
oxidoreductase, decarboxylase, and aminotransferase activity, to carry out the chemically 
challenging transformation of an aromatic methyl group to an amine. Structural studies suggest a 
role for numerous active-site residues in this transformation, which are further corroborated by 
site-directed mutagenesis, and analysis of the bound ligands produced both in vivo and in vitro. 
Structural studies of a subset of these variants highlight that conformational changes occur at the 
active site in the presence or absence of bound substrate, and that multiple, complementary 
interactions throughout the entirety of the ligand are necessary to orient the substrate for productive 
catalysis. Further, structure-function studies can provide insights into the mechanism of these 
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reactions that are under progress. Such studies may be extrapolated for the biosynthesis of complex 
compounds that are difficult to synthesize otherwise. These studies would also open up more 
options for the biotechnological development of new molecules of medical importance. 
 
 

































Figure 2.1: (a) The key gene (rosB) responsible for the formation of AF through systematic gene 




















Figure 2.2: Characterization of purified RosB: (a) SDS-PAGE gel image for purification of RosB-





















Figure 2.3: (a) Crystal structure of AFP-bound monomer unit, (b) RosB- tetramer; each monomer 
is shown with different colors (c) Size- exclusion chromatography spectrum along with standards 
(top); LC-trace for bound ligand, AFP (bottom), (d) RosB ligand omit map; electron density map 
represented as Fo-Fc contoured at 2.5 , each monomer is displayed with different color. Omit map 











































Figure 2.5: Structural similarity of RosB with FMN bound structures of Flavodoxin85 (in green) 


























Figure 2.6: (a) and (b) represent the active site WT and Y53F mutant form respectively, (c) Superposition 


























Figure 2.7: (a) and (b) represent the active site WT bound and unbound (Apo), respectively, (c) 



















































Figure 2.8: LC and UV profiles: (a), (b) and (c) represent LC profile of bound ligand in WT, 
Y53F, and R13A, respectively. (d), (e) and (f) represent UV profile of intermediates upon reaction 














Table 2.1: List of primers used for WildType and RosB variants 
All mutants were created my Quick-Change mutagenesis. The primers for wild type contain 




RosB-R13A-5' CTC AAC ACC ACT CTG GCG CGG TCA CCC AGC CGC 
RosB-R13A-3' GCG GCT GGG TGA CCG CGC CAG AGT GGT GTT GAG 
RosB-Y240A-5' ACC CCG GCC ATC CGC GCG AAG CGG TTC CAG AAG 
RosB-Y240A-3' CTT CTG GAA CCG CTT CGC GCG GAT GGC CGG GGT 
RosB-Y53F-5' GAC ATC GAG CAG GAG TTC TGG GAC GAC TAC GAC 
RosB-Y53F-3' GTC GTA GTC GTC CCA GAA CTC CTG CTC GAT GTC 
RosB-Y240F-5' ACC CCG GCC ATC CGC TTC AAG CGG TTC CAG AAG 




















Table 2.2: Crystallographic refinement parameters 
 Native Y53F_Apo Y53F_Bound 
Data collection    
Space Group I 4122 I 4122 I 4122 
Wavelength (Å)                             0.9789 1.2172 1.2172 
Cell: a, b, c (Å) 117.3, 117.3, 102.3 117.7, 117.7, 101.3         117.4,117.4,101.9 
Resolution (Å)1 82.9-1.7 (1.95-1.80) 83.2-2.1 (2.15-2.0)   83.0-1.9 (2.05-1.96) 
Total reflections 534,490 150,528 443,453 
Unique reflections 33,151 20,581 27,943 
I/(I) 14.9 (2.2) 18.3 (2.2) 18.2 (2.1) 
Completeness (%) 100 (99.9) 100 (96.7) 99.7 (96.1) 
Refinement    
Resolution (Å) 25.6-1.80 82.9-2.1 83.01-2.0 
No. reflections 31,218                  29,120 27,949 
Rwork / Rfree2 16.57/18.30              22.73/26.70 22.49/24.13 
Number of atoms    
Protein                   8004 8004 8048 
Ligand                  124 - 122 
Water                  224 242 224 
B-factors    
Protein                  15.9 20.1 30.0 
Ligand                 29.1 - 25.5 
Water                 22.9 24.1 26.4 
R.m.s. deviations    
Bond lengths (Å)               0.008 0.007 0.006 
Bond Angles (o)               1.021 1.228 0.910 
 
Ramachandran Plot 
   
Favored, outliers (%)             98.1, 0.0 97.8, 0.7   98.4,0.0 
    
1Highest resolution shell is shown in parenthesis. 
2R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% 




Table 2.3: HPLC purification method and sample composition for LC-MS 
Solvent A: Water w/ 0.1% FA; Solvent B: Acetonitrile w/ 0.1% FA; Flow rate: 1mL/min at 480 
nm; reverse phase C18 column 
  
FMN, TPP, and Glu represent flavin mononucleotide (substrate in the reaction), thymine 
pyrophosphate (co-factor) and glutamate (amine source), respectively. A, B, C, and D represent 






CHAPTER 3: Total Synthesis, Structural and Biochemical Characterization 
of Binding of a Signaling Molecule, Avenolide, to its Cognate Receptor in S. 
avermitilis 
Introduction      
Since the discovery of A-factor (Figure 3.1(a)), the first identified member of the γ-
butyrolactone family from Streptomyces griseus species in 1967, small molecules have been 
regarded as microbial hormones that have the ability to change the expression profiles of 
streptomycetes drastically.1,2 A-factor has been shown to facilitate sporulation and streptomycin 
production in mutant strains that otherwise lack the ability to do so.3,4 Extensive work has been 
done since then to show how streptomycetes regulate biosynthetic gene clusters involved in 
secondary metabolism.5 Due to the essential role A-factor plays in the biosynthesis of  the 
antibiotic streptomycin, an aminoglycoside antibiotic that has been listed on the World Health 
Organization’s List of Essential Medicines for treating tuberculosis as well as other bacterial 
infections,  it has been a popular subject of research in the field of bacterial signaling.6,4,7 The  
biosynthesis of A-factor has been well studied and the intracellular target of A-factor, the TetR 
family GBL receptor, transcriptional repressor protein ArpA, has also been identified.8 Similar to 
the role of ArpA in the regulation of secondary metabolite production and morphological 
differentiation, there have been a variety of other ArpA-like putative GBL receptors that have been 
reviewed.  
It has been observed that not all ArpA homologs bind γ-butyrolactones; in fact, depending 
upon the small autoregulatory molecules they bind to, these rreceptors are currently categorized 
into three classes based on the difference in the core chemical structure of their cognate ligands.10 
The most well studied among these is the bona fide γ-butyrolactone receptors that have already 
been discussed in detail in chapter 1. These receptors bind γ-butyrolactones that vary primarily in 
chain length and branch identity. The second class of homologous receptors is the ‘pseudo’ γ-
butyrolactone receptors, which have very high amino acid sequence similarity to the bona fide 
receptors but, rather than binding to canonical GBLs, they bind to structurally diverse secondary 
metabolites like ScbR2 and regulate the production of bioactive small molecules like actinorhodin, 
undecylprodigiosin, and jadomycin B in response.11,12 The third class of these, the TetR family 
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transcriptional repressors, bind to the butenolide-type of extracellular signaling molecule auto 
regulators such as avenolide (compound 13) (Fig.3.1(b)).  
Nihira T. and colleagues discovered a low-molecular-weight signaling molecule, a 
representative butenolide-type streptomyces hormone, avenolide [(4S,10R)-10-hydroxy-10-
methyl-9-oxo-dodec-2-en-1,4-olide)], in 2011.13 It was reported  that avenolide autoregulates the 
production of the antibiotic avermectin in the industrially important microorganism S. 
avermitilis.13,14. However, unlike the bona fide γ-butyrolactones whose biosynthesis has been 
widely understood, not much is known about avenolide’s biosynthesis.13,8 Studies performed by 
the same group also suggested that the avenolide-mediated regulation of avermectin is due to its 
binding to its cognate receptor, AvaR1. As described briefly in chapter 1, AvaR1 is a member of 
the TetR family of transcriptional repressors and thus inhibits transcription by binding to specific 
DNA sequence. Binding of avenolide to AvaR1 in S. avermitilis releases the bound DNA and 
activates transcription that in turn leads to the production of avermectin. Figure 3.3 (a) depicts the 
cartoon representation of avenolide-mediated regulation of avermectin production.  
Avenolide is composed of a butenolide structure containing two stereocenters, differentiating 
it from most of the Streptomyces canonical -butyrolactone type autoregulators. The other 
synthetic stereoisomers of avenolide (4S,10S and 4R,10R) were shown to dramatically reduce the  
dissociation activity against the AvaR1–DNA complex compared to that of (4S, 10R)-avenolide, 
suggesting the importance of absolute configuration in the signaling cascade.15 Studies suggest 
that avenolide regulates the production of avermectin, an anthelmintic compound, and triggers its 
production with a minimum effective concentration in the low nanomolar range.10   A semi-
synthetic derivative, ivermectin, has been widely used as an antiparastic agent for the past several 
decades, with annual world sales of $850 million.13  
Knockout studies revealing the significance of three particular genes (aco, cyp17 and avar1) 
were also carried by Kitani et al.  This information provided some basis to understand the putative 
roles of these involved genes. Reported experimental observations that aco mutant generated lead 
to decreased levels of avermectin in S. avermitilis suggest that  biosynthesis of avenolide requires 
the enzymatic functions of Aco (a putative acyl-CoA oxidase) and Cyp17 (a putative cytochrome 
P450 monooxygenase)(Fig.3.2a and 3.2b)13 and is regulated by the AvaR1.14,16 
Kitani et al. had previously identified four Streptomyces gene clusters containing a similar 
genomic context to that of aco, avar1, and cyp17 as found in S. avermitilis to produce avermectin.13 
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This information helps tentatively identify receptors of a given subclass from given genomic 
contexts. Additionally, bioinformatics analyses performed by one of my collaborators, Phil 
Olivares, revealed that there are at least 63 sets of putative butenolide receptors and butenolide 
biosynthetic gene clusters in various species of Streptomyces. Importance of studying the 
regulation mechanism of this AvaR1-avenolide regulatory system can also be supported by the 
fact that ivermectin, a semisynthetic analog of avermectin,  is a widely used broad-spectrum 
antiparasitic drug used to treat river blindness and lymphatic filariasis, amongst other infections, 
and has been used for more than four decades.17 
The recent discovery of avenolide activity, measured by percentage of strains producing 
avenolide-type signaling hormones, observed in about 24% of actinomycetes by Nihara group and 
colleagues suggests that other active Streptomyces strains can also produce avenolide or avenolide-
like compounds to regulate secondary metabolism.18 This shows that there could be other 
avenolide like molecules that are involved in the regulation of secondary metabolites in other 
Streptomyces strains. The signature features in avenolide or avenolide-like compounds  is the 
presence of the C-10 hydroxy group that has shown to be important for the binding activity of 
avenolide to the AvaR1 receptor.13 Four recently identified butenolide compounds also establish 
the significance of the C-10 hydroxy group, as the compounds lacking C10 hydroxy display very 
low activity.16,19 Based on the small number of characterized butenolide structures and the varied 
structures of the γ-butyrolactones, it appears that there is a conserved head group moiety along 
with a more variable alkyl tail in terms of oxidation, length, and branch identity. 
Based on studies carried out through the past several years, it has been observed that the 
homologous receptors described here not only regulate the production of medically relevant drugs 
and drugs of varying scaffold types, but they also suggest that all secondary metabolites are not 
regulated by these receptors. Therefore, I hypothesized that a detailed understanding of the 
mechanism of regulation of avermectin production by avenolide, could help elucidate the genetic 
understanding of regulatory mechanisms for production of clinically relevant natural compounds. 
This would also lead to the discovery of these novel compounds by unlocking the natural product 
biosynthesis for a wide number of silent gene clusters containing homologous gene arrangements 
that would broaden the chemical tool box to fight against infection and the developed resistance.  
Due to the lack of structure of any GBL receptor so far, not much is known about the structure-
function relationship between signaling molecules and regulatory receptors in these systems.  
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Additionally, observed 40% sequence homology between γ-butyrolactone receptors like ArpA and 
AvaR1 along with the lack of structural information revealing ligand and receptor interactions 
motivated us to investigate the nature of such interactions. Efforts have been made in the past to 
help differentiate between these receptor classes via structural or functional studies but have been 
met with varied success. Therefore, further structural and biochemical studies of avenolide -AvaR1 
binding interactions would provide more insight into the regulatory mechanism of other microbial 
antibiotic production by helping to develop analogs to activate these cryptic gene clusters. With 
this understanding, we aimed to determine a co-crystal of AvaR1 and avenolide. 
The unusual chemical properties and inherent stability along with the important medical 
relevance of avenolide made the AvaR1-avenolide system a target for crystallization and structure 
determination.15 Butenolides signaling molecules  are found to be stable at high temperature (100 
oC for 30 min), strong acidic conditions (pH 1 for 30 min), and even at strong basic conditions(pH 
11 for 10 mins) unlike well studied -butyrolactones which acid and base labile due to presence of 
lactone rings13 To overcome the inaccessibility issue of avenolide, I also developed a total 
synthetic route to synthesize avenolide and then utilized that for further structural and biochemical 
studies.  
 
Results and Discussion 
To obtain the crystal structure and to gain more insights into the mechanism of regulation of 
avenolide-AvaR1 interaction, efforts were put forward by my collaborator, Phil Olivares, who was 
able to clone, express, purify, and crystallize AvaR1. He was able to solve the crystal structure of 
AvaR1 alone at 2.3Å resolution. The obtained structure supports the observation that AvaR1 
belongs to the TetR superfamily of proteins and it exists as a homodimer, like other transcription 
repressors of this family, with each monomer containing two separate domains: a ligand-binding 
domain and a DNA-binding domain, the latter of which was expected to undergo a conformational 
change upon binding to avenolide. (Figure 3.3 b). Therefore, the next relevant experiment was to 
attempt to get the co-crystal structure of AvaR1 with avenolide bound in order to understand the 
mechanism of transcriptional activation in the presence of avenolide, depicted in figure 3.3a. 
In order to carry out these structural studies, access to the stereospecific small molecule was 
not trivial. According to the report by Nihara and colleagues, only 1.2 mg of avenolide was isolated 
from 2000 L of cell culture. Additionally, not much is known about the biosynthesis of avenolide, 
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unlike the biosynthesis of canonical GBLs which is well understood and  has commercially 
available precursors.20 Studies reported by Kitani et al. and experiments performed by Phil suggest 
the putative role of aco (involved in cyclization to make lactone type ring), cyp17 (involved in the  
dihydroxylation) and AdhA5 (to catalyze dehydrogenation to the C=C double bond) in avenolide 
biosynthesis, but the order of reactions and, again, the starting materials are unknown. 
The lack of biosynthetic information along with the detailed retrosynthesis reported by the 
same group motivated us to chemically synthesize the molecule rather than isolating it 
biochemically.15 Avenolide can be retro synthesized using the convergent approach reported by 
Nihira group from Japan (Scheme 3.1) where 13 could be obtained from epoxide 10 via Grubb’s 
ring closing metathesis reaction, which itself could be produced from iodide 11 and aldehyde 12.15 
 
Scheme 3.1: Convergent retrosynthetic analysis of (4S,10R)-avenolide 
Detailed experimental procedures, NMR, and mass spectroscopic data are provided in the 
materials and method section. Briefly, multi-step total synthesis of 13 was started with the 
Sharpless asymmetric dihydroxylation of commercially available 1-methyl-2-butene using AD-
mix- which afforded the diol 14 with specified stereochemistry, in 92% yield.21 The absolute 
stereochemistry was confirmed with the optical rotation []26 +1.93 which are in proper agreement 
with the reported value.15 After acetal formation of the chiral diol, subsequent DIBALH reduction 
resulted in intermediate 15 which upon Swern oxidation furnished the desired aldehyde 12 with 




Scheme 3.2: Synthesis of key intermediate 12 
Another fragment 11 was derived from a commercially available 1,5-pentanediol by mono 
TBDPS protection followed by Swern oxidation, resulting in aldehyde 17. Wittig olefination and 
subsequent DIBALH reduction produced E-allyl alcohol 18. A coupling constant (J) of 15.1 MHz 
between the two olefinic protons, obtained from 1H NMR (500 MHz), confirmed the formation of 
E-isomer selectively.22 18 was then converted to primary alcohol 19 by two-step sequential 
reactions of alcohol protection by THP group followed by deprotection of TBDPS group using 
TBAF, respectively. Mesylation of 19 to provide a better leaving group to facilitate the following 
nucleophilic substitution (SN
2) with sodium iodide gave the desired key intermediate 11 (Scheme 
3.3). 
 
Scheme 3.3: Synthesis of key intermediate 11 
 Aldehyde 12 was then coupled with iodide 11 via halogen-lithium exchange of iodide with t-
BuLi to generate alcohol 20 as a diastereomeric mixture. The mixture of these diastereomers was 
used directly, without further purification, to afford keto alcohol 21 via two steps including Swern 
oxidation, followed by THP deprotection. Subsequent Sharpless asymmetric epoxidation with (+) 





Scheme 3.4: Synthesis of epoxy intermediate 10 
Stereospecific epoxy alcohol 10 was converted into allyl alcohol 22 in a single step by using 
titanocene dichloride and Zn powder. The allyl alcohol was then treated with acryloyl chloride to 
yield dialkene 23. The final product, stereospecific (4S, 10R)-avenolide, was then produced by 
ring-closing metathesis of 23 treating the dialkene with Grubb’s second-generation catalyst 
(Scheme 3.5). Studies reported by Kitani et al. highlight the role of stereospecific carbon in the 
avenolide (4S,10R) activity, which was reduced by half in the presence of its diastereomer 
(4S,10S). The stereoselectivity was confirmed by measuring optical rotation of the final compound 
which correlates perfectly well with the reported value. 
 
Scheme 3.5: Synthesis of (4S, 10R)-avenolide 
Thus, I was able to synthesize optically pure avenolide in 16 fewer steps (total 24 chemical 
steps) than what was reported by Nihara group with 99% purity as measured by NMR. The route 
developed is also advantageous over the reported route because it not only reduces the number of 
steps but also avoids the use of toxic cyanide-containing chemicals. The compound was also 
obtained in good yield (14 mg total from 15g of starting material) and was more than enough for 
all the binding, activity, and crystallographic studies. After achieving access to avenolide, we 
40 
 
sought to determine the co-crystal structure with AvaR1. The broom-shaped crystals were obtained 
with 1mM avenolide in 300mM KCl and 20mM HEPES pH 7.5; this stock was used for all the 
biochemical and crystallographic experiments. Crystals obtained in 25% PEG 3350 and 0.1M 
sodium acetate trihydrate pH 4.5 with 1mM avenolide incubated with 14mg/ml AvaR1 were not 
high-quality crystals, thus they were optimized further and resulted in single, needle-shaped 
crystals. The crystals diffracted to 2.0 Å, but electron density of bound ligand wasn’t observed 
upon solving the structure. Thus, more hanging drop crystallization trays were set up with 14 
mg/mL protein incubated with 3mM avenolide in 23% PEG 3350 and 0.1M sodium acetate 
trihydrate pH 4.5. Like in the previous trial, we were able to solve the crystal structure to 2.0 Å. 
This effort was successful, and we could observe the electron density for the bound ligand. Upon 
model building, further processing, and final refinement, we observed that in the AvaR1 
homodimer, one equivalent of the ligand was bound in the ligand binding domain per monomer. 
(Figure 3.5).  
Binding of AvaR1 with avenolide was also studied by Isothermal Titration Calorimetry (ITC); 
the heat change in this exothermic binding interaction was measured by titrating 80 M avenolide 
to 8 M AvaR1 at a constant rate. The isotherm showed the point of inflection at molar ratio N=1 
which suggested 1:1 binding of ligand per monomer, which agreed with the results obtained from 
our crystal structure (Figure 3.5(a) and (b)). The experiments were performed in triplicates but 
only one of the trials is shown in figure 3.4b. The isotherm also gave the strength of the binding 
interaction with Kd = 42.5nM ± 2.1 nM after three independent trials. The low nanomolar binding 
constant obtained matched well with the reported value of ~4nM by Kitani et al. obtained using 
gel shift based assays.13 The concentrations used in the experiment, a detailed procedure, and 
experimental parameters are provided in detail in the materials and methods section.  
By looking into the binding site of the AvaR1 with bound avenolide structure more closely, 
the ligand was aligned in a way depicted in figure 3.6 (a) (left), where residues have hydrophobic 
interactions with the lactone ring of the ligand and with the aliphatic carbon chain. The structure 
represented here has one ligand bound to one monomer, and, due to symmetric structure, another 
monomer also behaves in the same manner. The residues that have direct interactions with the 
ligand structure are highlighted in the figure. The structure revealed the major conformational 
changes in the binding pocket induced by avenolide binding. Thr163 and Gln166 residues interact 
with the lactone ring structure; specifically, Gln166 interacts with the polar functional groups and 
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Thr163 has hydrophobic interactions with the lactone ring. Gln166 showed a significant 
conformational change from the structure with bound avenolide (orange) to the structure without 
bound avenolide (blue). Similarly, Thr132 is present beside the methyl group in the tail, adding to 
the hydrophobic interactions. The C-10 hydroxy group is aligned well with the hydroxyl group of 
Tyr186 and within hydrogen-bonding distance. Residues Leu89, Val159, and Val106 are aligned 
along the hydrophobic alkyl chain of avenolide. Trp128, Gln65, and Tyr109 residues display 
hydrophobic interactions, aligned along the domain interface and move the domains to fit into the 
binding site, leading to shifting of domains.  
Therefore, binding of avenolide to AvaR1 induced a significant conformational change (~20o) 
in the DNA-binding domain of one monomer, as shown in the overlaid structures shown in figure 
3.6(b), and this presumably results in its release from its cognate DNA, activating the transcription. 
The crystallographic parameters, refinement statistics, and other details are mentioned in table 3.3 
in the methods section. 
To further understand the mechanism of avenolide-regulated production of avermectin in S. 
avermitilis, we then decided to investigate the binding interactions of AvaR1 with the acoARE 
DNA sequence13 The AvaR1 binding site on the acoARE sequence, identified in the upstream 
region of the aco gene by Kitani et al. through the DNase I footprinting analysis, is highlighted in 
Figure 3.7 (a). To design the AvaR1-binding oligonucleotide sequences for crystallographic 
studies, the sequence is split into two halves due to symmetry in the protein structure (Figure 3.6 
(a)). Oligonucleotides designed this way are self-annealing i.e. first half of the sequence is 
complementary to the second half.  
In order to obtain the crystal structure of AvaR1 bound to its cognate DNA, efforts were 
undertaken by Phil Olivares in which he attempted crystallizing AvaR1 with a variety of different 
DNA oligonucleotides based on the aco-ARE sequence as the base sequence. These sequences 
contained 5’- or 3’- overhangs of different lengths, including acoARE with a single base pair 
overhang (acoARE+1), acoARE +4, and acoARE +5 sequences, highlighted in yellow in table 
3.1. Upon setting up crystallization trays in which AvaR1 was incubated with each respective DNA 
oligonucleotide, crystals appeared within a day or two after optimization. Unfortunately, none of 
the crystals diffracted to below 15Å. Continued efforts to obtain the DNA-bound crystal structure 




Thus, the next idea was to design oligonucleotides based on the symmetric structure of the 
AvaR1 homodimer.  Newly designed palindromic oligonucleotide sequences were tried for co-
crystallization with AvaR1 which were designed using the first half of acoARE sequence 
(highlighted in cyan) or the second half (highlighted in pink) of the symmetric sequence. Resulting 
oligonucleotides designed in this manner were self-annealing; that is, the first half of the sequence 
is complementary to the second half. All the sequences are listed in Table 3.1, where Pal in the 
name denotes the palindromic sequences. 
For crystallization, DNA oligonucleotides were incubated with AvaR1 (14mg/mL) in 1.2:1 
molar ratio by using one monomer per half of the palindromic sequence for 30 minutes on ice 
before setting up the trays. Significant improvements were observed in the resolution of diffraction 
data for the palindromic sequences; the resolution increased to 6-7Å from 15Å. Thus, more 
palindromic oligonucleotide sequences were designed using overhangs of varying length, along 
with varying both the 5’- and/or 3’- end(s). Among all the above sequences tried, Pal2-1each 
(which signifies as Palindromic sequence designed using second half and have 1 nucleotide less 
on each end) resulted in symmetric, hexagonal cylindrical-shaped crystals in 0.1M sodium 
chloride, 0.1M Tris pH 8.0, 15% ethanol, and 5% MPD as precipitants and diffracting to 3.7Å. 
These dramatic improvements motivated us to utilize oligonucleotides designed based on the Pal2-
1each sequence by adding or removing a varied number of nucleotides from either the 5’- or 3’- 
end. Using this rationale, new sequences, Pal2-1each-5’-AT and Pal2-1each-5’-GC, gave high 
quality crystals and diffracted to 3.2 Å and 3.1 Å, respectively. Upon further processing and 
solving the crystal structure, significant electron density was observed for the oligonucleotide next 
to the DNA binding domain of AvaR1 (Figure 3.6 (b) bottom right); however, some 
conformational rearrangements were observed as anticipated. 
This structural information revealed that the DNA sequences were shown bound to only half 
of the receptor domains (i.e. to one monomer) and this provoked us to think about the length of 
these designed oligomers. New oligonucleotides, designed with G, GC, and GCGC as linkers to 
test whether the oligos needed to be longer in order to be bound in the DNA-binding domain of 
both monomers simultaneously, were then co-crystallized with AvaR1.  However, these alterations 
in the DNA sequences did not significantly improve diffraction resolution, thus further 
optimization and studies are required to get a higher resolution structure.  
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These structural studies of AvaR1 with avenolide and DNA oligonucleotides provided more 
insights into the mechanism of avenolide-mediated regulation of avermectin production. These 
studies could help activate silent gene clusters found in other Streptomyces strains containing 
homologous gene arrangements to those found in S. avermitilis for avenolide biosynthesis.  
Following these studies, we planned to investigate if avenolide activates any other downstream 
processes in either S. avermitilis or in other Streptomyces containing homologous gene clusters. 
Out of the 63 strains of Streptomyces containing homologous gene clusters based on the prior 
bioinformatic studies (Table 3.2), we chose two strains which we had ready access to and observed 
the effect of exogenous avenolide on their growth and/or morphology (Figure 3.7).  A slight change 
in color was observed in S. viridosporus and in S. pheaochromogenes in the presence of 
synthesized avenolide compared to the controls lacking exogenous synthetic avenolide as shown 
in figure 3.7. This color change could be due to new secondary metabolites produced; this 
morphological change is currently under further investigation.  
The Streptomyces strains containing gene clusters with homologous cyp and aco genes listed 
in Table 3.2, provide more opportunities to study the regulation of further downstream processes 
in these Streptomyces strains induced by either avenolide or its other synthetic analogs. Having 
developed a total synthetic route, various structural derivatives of avenolide can now readily be 
synthesized. These studies could lead to the discovery of new biologically active compounds. 
Additionally, knowing the synthetic route for the production of avenolide, starting materials, and 
the order of the reaction can be suggested to understand the role of enzymes involved in the 
biosynthesis of avenolide, which is under progress. 
 
Conclusions 
            An efficient and convergent total synthetic route for a small signaling molecule, avenolide, 
was established in 24 synthetic steps, and the optically active and extremely pure product was 
obtained via this synthetic scheme. This synthetic route can be modified to synthesize other 
analogs and, thus, other members of the butenolide-type family of signaling molecules. Avenolide 
belongs to a unique butenolide class of autoregulators which, upon binding to its cognate receptor, 
a TetR family of transcriptional repressor protein AvaR1, helps regulate the production of a 
medically-relevant natural product avermectin in S. avermitilis. High resolution crystal structures 
were obtained for AvaR1 alone, revealing its homodimeric nature, AvaR1 with the avenolide 
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ligand bound, and AvaR1 with DNA oligonucleotides bound, providing more insights into the role 
avenolide plays in regulating the production of avermectin in S. avermitilis. These studies also 
provide a foundation upon which to study other members of the butenolide class of signaling 





Materials and Experimental Procedures 
           All commercially available chemicals were purchased by the Aldrich Company and Fischer 
Scientific and used without further purification unless otherwise specified. Anhydrous solvents 
were either purchased from Fischer scientific and Aldrich or borrowed from solvent dehydrating 
system (SDS) in other labs at UIUC. All the oligonucleotides used in the study were purchased 
from Integrated DNA Technology (IDT). IPTG and antibiotics were purchased from Gold 
Biotechnology. 
 
 Instrumentation  
             High and low-resolution mass spectra were obtained by the Mass Spectrometry 
Laboratory, School of Chemical Science, University of Illinois. Mass spectra were obtained by 
field desorption (FD) on a Waters 70-VSE-A and by ESI on a Waters Micromass Q-Tof. Other 
instruments like rotatory evaporator (Isotemp) and stirring plates (Cole Palmer) were purchased 
from Fischer Scientific. 
             Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Unity 500 or 
Varian INOVA 500NB or Varian Unity 400 spectrometers at 21±3 °C unless otherwise mentioned. 
Chemical shifts (δ) are reported in parts per million (ppm). Coupling constants (J) are reported in 
Hertz. 1H NMR chemical shifts were referenced to the residual solvent peak at 7.26 ppm in 
chloroform-d (CDCl3) or other deuterated solvents as stated. 
13C NMR chemical shifts were 
referenced to the center solvent peak at 77.16 ppm for CDCl3. Analytical thin-layer 
chromatography (TLC) was performed on 0.2 mm silica 60 coated on glass plates with F254 
indicator for monitoring all the reactions. PMA, KMnO4, anisaldehyde, ninhydrin and iodine were 
used for staining TLC plates to detect various functional groups. Flash column chromatography 
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was performed on 40–63 µm silica gel (SiO2). Solvent mixtures used for chromatography are 
reported as percent volume (%) or as volume ratio (v/v). 
            
Cloning and Overexpression of recombinant AvaR1-MBP from E. coli. (provided by Phil 
Olivares) 
        Wild type protein was cloned by Ligation Independent Cloning (LIC) using specific LIC 
primers by Phil Olivares. It was grown in an identical manner for crystallization as mentioned in 
chapter 2, while preparation of the selenomethionine (SeMet) labeled proteins was carried out by 
the repression of methionine synthesis in defined media.24  Cells were pelleted at 3566 x g before 
resuspension with 500 mM NaCl, 10% glycerol, and 20 mM Tris pH 8.0 for lysis. A 6 °C chilled 
cell homogenizer (Avestin) was utilized for cell lysis using 4 passes at 7,000 psi. Soluble protein 
was then separated from the insoluble fraction for 1 h at 15,400 x g at 4 °C. The protein was loaded 
onto a HisTrap HP column (GE Healthcare) and washed with 50 mL of 1 M NaCl, 20 mM Tris 
pH 8.0, 30 mM imidazole. A 40 mL gradient elution was performed over 20 min starting from the 
aforementioned wash buffer to 1 M NaCl, 20 mM Tris pH 8.0, 250 mM imidazole. The MBP tag 
of SeMet-MBP-AvaR1 was removed over 12 h via cleavage with thrombin protease with a 
simultaneous 2-fold dilution of SeMet-MBP-AvaR1 into dialysis buffer. This dialysis buffer was 
comprised of 10% glycerol, 5 mM 2-mercaptoethanol, 300 mM KCl, 20 mM HEPES pH 7.5. 
Removal of the affinity tag was followed by size exclusion chromatography using an 
ÄKTApurifier with attached Superdex HiloadTM 75 16/60column (GE Healthcare) and a flowrate 
of 1 mL min-1 of running buffer. Size exclusion chromatography buffer for all AvaR1 variants 
consisted of 300 mM KCl, 20 mM HEPES pH 7.5. Protein was concentrated, when needed using 
Amicon® Ultra Centrifugal Filters. 
 
Co-Crystallization of AvaR1 and Avenolide 
         Similar technique was used for co-crystallization of AvaR1 and avenolide. Purified protein 
was concentrated using Amicon centrifugation filter (10kDa MWCO) to 24 mg/ml and protein was 
stored at -80oC in 100uL eliquotes. 14mg/mL protein was incubated with 3mM avenolide (used 
from 10mM stock in 300mM KCl, 20mM HEPES pH 7.5) for 30 minutes on ice. The mixture was 
diluted with gel filteration buffer (300mM KCl and 20 mM HEPES pH 7.5). Co-crystals were 
obtained by vapor diffusion methods using the Gryphoon (Art Robbins Instruments (ARI), USA) 
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robotic system using 0.4 L drops and commercially available crystallization kits from Hampton 
Research and Molecular Dimensions. Each drop contained equal volume of well condition and 
protein solution.  Optimized crystal conditions were determined through hanging drop or sitting 
drop vapor diffusion methods with 2 µL drops comprised of equal volumes of protein solution and 
crystal condition. When stated, defined cryoprotective solutions were used prior to the vitrification 
of protein crystals in preparation for data collection.  Cryoprotective solutions were modified well 
conditions supplemented with the noted concentration of cryoprotectant.  All X-ray diffraction 
data collection was at the Life Sciences Collaborative Access Team (Sector 21) at Argonne 
National Laboratory in Lemont, IL. 
        The crystallization parameters for the best diffracting crystals are given in Table 3.3. Crystals 
obtained in different salt and precipitant conditions were frozen by direct immersion into liquid 
nitrogen. Initial crystals were obtained in Index D5 (25% PEG3350 and 0.1M sodium acetate 
trihydrate pH 4.5) which upon further optimization gave very good quality diffraction crystals in 
23% PEG3350 and 0.1M sodium acetate trihydrate pH 4.5 at 4 oC using hanging drop 
crystallization. Crystals were submerged briefly in the crystallization media supplemented with 
25% ethylene glycol to serve as a cryoprotectant prior to vitrification in liquid nitrogen. Structure 
of apo AvaR1 obtained by Phil was used to determine crystallographic phases. 
 
Co-Crystallization of AvaR1 and oligonucletides 
          Similar method was used for co-crystallization of AvaR1 with different oligonucleotide 
sequences designed based on the AvaR1 DNA binding site on the upstream of acoARE gene. For 
that 14mg/mL purified and concentrated dimeric protein was incubated with individual 
oligonucleotide sequences (shown in table 3.1) in 1:1.2 molar ratio, for 30 minutes on ice. 
Palindromic DNA squences were first annealed and then double stranded DNA was used from 1 
mM stock prepared in 20mM MgCl2, 50mM Tris pH 8.0 buffer. Buffer, DNA and protein were 
added in respective order. For some oligonucleotides, white turbid solution was obtained as soon 
as protein was added, a few Ls of 8M ammonium acetate was added to avoid the turbidity 
followed by incubating at either room temperature or on ice, until we saw the clear solution. 
Mixture thus obtained was used to screen different commercially available conditions using 
Gryphoon robot from Art Robbins in 96-well intelli trays, with each drop being 0.4 L. The trays 
were set up at 4 oC and every oligonucleotide crystallized in different conditions and produced 
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different quality and morphology of crystals. The best quality and best optimized crystals were 
then radiated using X-ray at Argonne national Lab, Lemont, IL. 25 % ethylene glycol was used as 
cryoprotectant to freeze the crystals for all the AvaR1-oligonucleotide co-crystals. 
 
Isothermal Titration Calorimetry 
            ITC measurements were performed at 25 °C on a MicroCal VP-ITC calorimeter. A typical 
experiment consisted of titrating 7 µL of a ligand solution (80 µM) from a 250 µL syringe (stirred 
at 300 rpm) into a sample cell containing 1.8 mL of AvaR1 solution (8 µM) dissolved in 300mM 
KCl, 20mM HEPES pH 7.5 with a total of 35 injections (2 µL for the first injection and 7µL for 
the remaining injections). The initial delay prior to the first injection was 60s, with reference power 
10. The duration of each injection was 16s and the delay between injections was 400s. All 
experiments were performed in triplicates. Data analysis was carried out with Origin 5.0 software. 
Binding parameters, such as the dissociation constant (Kd), enthalpy change (∆H), and entropy 
change (∆S), were determined by fitting the experimental binding isotherms with appropriate 
models (one-site binding model). The ligand stock solution was prepared 10 mM in 300mM KCl 
and 20mM HEPES pH 7.5. The buffer solutions for ITC experiments contained 300 mM KCl and 
20 mM HEPES pH 7.5. 
 
Total synthetic schemes and experimental procedures: 
Synthesis of aldehyde fragment: 
 
(R)-2-Methylbutane-1,2-diol (14): To a stirred solution of the 2-methyl-1-butene (3.75 g, 53.47 
mmol) in t-BuOH: H2O (1:1, 400 ml) were added K3Fe(CN)6 (52.81 g, 160.41 mmol), K2CO3 
(22.17 g, 160.41 mmol), K2OsO4(OH)4 (197 mg, 0.54 mmol, 1 mol%) and (DHQD)2PHAL (416.5 
mg, 0.54 mmol, 1 mol%) at 0 oC under Ar atmosphere. The reaction mixture was stirred for 24 h 
at 0 oC using Ar balloon. The reaction was quenched with a saturated aqueous solution of Na2S2O3 
and the aqueous phase was extracted with EtOAc (2x1L). The water layer was thoroughly washed 
with EtOAc and combined organic extracts were washed with brine (saturated NaCl) and dried 
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over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography with a gradient from 30% EtOAc/hexanes to 70% EtOAc/hexanes to 10 % 
MeOH/DCM, to afford 14 (3.5 g, 82%) as a colorless oil. Spectroscopic characterization 
parameters agreed with the reported mass and chemical shift values.15  
[]25 +4.96 (c 1.0, CHCl3); 1HNMR (500 MHz, CDCl3)  3.47 (brs, 2H), 3.43 (d, J = 11.1 Hz, 
1H), 3.37 (d, J =11.1 Hz, 1H), 1.51 (q, J =7.3 Hz, 2H), 1.10 (s, 3H), 0.89 (t, J =7.6 Hz, 3H); 13C-
NMR (125 MHz, CDCl3)  73.6, 69.3, 31.2, 22.5, 8.2 HRMS (ESI+, TFA-Na) calcd for 
C5H12NaO2 127.0735 [M+Na]
+, found m/z 127.0740. 
(R)-2-((4-Methoxybenzyl)oxy)-2-methylbutanal (12): To a solution of 1 (388 mg, 3.73 mmol) in 
CH2Cl2 (15 ml) were added PPTS (46.85 mg, 0.185 mmol) and p-anisaldehyde dimethylacetal 
(0.63 ml, 3.73 mmol) at rt under N2. After stirring for 5h at rt, the reaction was quenched with 
water and the aqueous phase was extracted with EtOAc (2 x 30mL). The combined organic extracts 
were washed with brine and collected organic extracts were dried over anhydrous Na2SO4 and 
concentrated in vacuo using rotatory evaporator. The dried residue was purified by flash column 
chromatography (15% EtOAc/hexanes) to afford the corresponding p-methoxybenzylidene acetal 
(0.595g, 92%) as a colorless oil. 
1 H-NMR (500 MHz, CDCl3)  7.42 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 5.81 (s, 1H), 
3.83 (s, 2H), 3.81 (s, 3H), 1.79–1.62 (m, 2H), 1.38 (s, 3H), 0.99 (t, J = 7.5 Hz, 3H); 13C-NMR 
(125 MHz, CDCl3)  160.2, 130.5, 128.1, 113.6, 103.3, 81.7, 75.3, 55.2, 31.1, 24.2, 8.6; HRMS 
(ESI+, TFA-Na) calcd for C13H19O3: 223.1334 [M+H]+, found m/z 223.1332.  
       To a solution of the p-methoxybenzylidene acetal (300 mg, 1.35 mmol) in CH2Cl2 (15 ml) 
was added DIBALH (1.02 M in hexanes, 4.00 ml, 4.05 mmol) at -78 oC under N2. After stirring 
for 1 h at 0 oC, the reaction was cautiously quenched with MeOH at 0 oC, diluted with CH2Cl2 (30 
mL) and treated with celite (1.20 g) and Na2SO4.10H2O (1.20 g). The mixture was allowed to 
warm to rt. After stirring at rt for 2h at rt, the mixture was filtered through a celite pad, washed 
with DCM a couple of times and the filtrate was concentrated in vacuo. The residue was purified 
by flash column chromatography (25% EtOAC/ hexanes) to give the corresponding alcohol 15 
(140 mg, 92%) as a colorless oil. 
1H-NMR (500 MHz, CDCl3) 7.27 (d, J = 10 Hz, 2H), 6.89 (d, J = 10 Hz , 2H), 4.9 (s, 2H), 3.82 
(s, 3H), 3.59 (d, J = 10 Hz, 1H), 3.55 (d, J = 10 Hz, 1H), 2.41 (brs, 1H), 1.66 (dq, J = 2.3 Hz, 7.4 
Hz, 1H), 1.25 (s, 3H), 0.95 (t J = 7.5 Hz, 3H); 13C-NMR (125.0 MHz, CDCl3)  159.1, 131.1, 
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129.1, 113.9, 77.9, 66.9, 63.4, 55.3, 27.8, 19.7, 8.1; HRMS(ESI) calcd for C13H19O3 ; 223.1334 
[M+H]+, found m/z 223.1338. 
     A solution of the oxalyl chloride (1.15 mL from 2M stock in DCM, 2.23 mmol) in dry CH2Cl2 
(7 mL) was cooled to -78 oC under an atmosphere of Ar. A solution of dry DMSO (316 L in 2mL 
DCM, 4.46 mmol), was added slowly until temperature is maintained below -65 oC. After stirring 
for 5 min, a solution of 2 (500 mg, 2.23 mmol) in dry CH2Cl2 (3 mL) was added slowly, and 
resulting mixture was stirred slowly for 15 min, after which, Et3N (1.55 mL, 11.14 mmol) was 
added slowly. After stirring the reaction for 10 additional min at -78 oC, the cooling bath was 
removed, and the reaction was allowed to warm for about 45 min to rt. Upon reaching room 
temperature, water (10 mL) was added and stirring continued for 15 min. The reaction mixture 
was then washed successively with 5 % HCl (10 mL), saturated NaHCO3 (10 mL) and brine (7 
mL) using a separatory funnel. Collected organic layers were combined and dried with anhydrous 
Na2SO4, filtered and concentrated under reduced pressure to afford crude oil.
25 Flash 
chromatography (20% EtOAc/hexanes) performed to get pure aldehyde 12 (430 mg, 94%) as 
yellow oil. Spectroscopic characterization parameters agreed with the reported mass and chemical 
shift values.15 
  1H-NMR (500 MHz, CDCl3)  9.67 (s, 1H), 7.32 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 10 Hz, 2H), 
4.42 (d, J = 17.5 Hz,1H), 4.38 (d, J = 17.6 Hz, 1H), 3.84 (s, 3H), 1.84–1.67 (m, 2H) 1.34 (s, 3H), 
0.95 (t, J = 7.5 Hz, 3H); 13C-NMR (500 MHz, CDCl3)  205.3, 159.3, 129.1, 113.9, 82.8, 65.8, 
55.3, 27.7, 17.7, 7.3; HRMS (ESI) calcd for C13H18NaO3 245.1154 [M+Na]+, found m/z 245.1152. 
 
Synthesis of alkene fragment: 
 
5-(tert-Butyldiphenylsilanyloxy)-pentanal (17): 1,5- pentanediol (5 ml, 47.5 mmol) and TBDPSCl 
(12.35 ml, 47.5 mmol) were added to a solution of NaH (1.94 g, 47.5 mmol) in anhydrous THF 
(158 ml) at 0 oC under N2 . The reaction mixture was stirred for 5 min at 0 
oC, then allowed to 
warm to rt. After stirring the reaction mixture for 2.5 h at rt, the reaction was quenched with cold 
H2O at 0 
oC, and the aqueous phase was extracted with CH2Cl2. The collected organic layer was 
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washed with brine and combined organic extracts were dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography (15% 
EtOAc/hexanes) to afford the corresponding TBDPS ether, 16 (14 g, 86%) as a colorless oil.15 
1H-NMR (500 MHz, CDCl3)  7.72 (d, 4H), 7.47-7.40 (m, 6H), 3.68 (t, J = 6.5 Hz, 2H), 3.68 (t, J 
= 6.5 Hz, 2H), 1.62-1.52 (m, 4H), 1.45-1.30 (m, 3H), 1.06 (s, 9H); 13C-NMR (500 MHz, CDCl3) 
 135.8, 134.3,129.3, 127.9, 64.1, 63.2, 32.7, 32.5, 27.1, 22.2, 19.5; HRMS (ESI +, calcd for 
C21H30O2Si 342.2015 [M+H]+, found m/z 342.2085.  
      A solution of dry DMSO (406 L in 2 mL dry DCM, 5.721 mmol), was added slowly, to a 
solution of the oxalyl chloride (1.43 mL from 2M stock in DCM, 2.86 mmol) in dry CH2Cl2 (7 
mL) cooled to -78 oC under an atmosphere of Ar, until temperature is maintained below -65 oC. 
After stirring for 5 min, a solution of TBDPS ether 4 (980 mg, 2.86 mmol) in dry CH2Cl2 (3 mL) 
was added slowly, and resulting mixture was stirred slowly for 15 min, after which, Et3N (1.99 
mL, 14.3 mmol) was added slowly. After stirring the reaction for 10 additional min at -78 oC, the 
cooling bath was removed, and the reaction was allowed to warm for about 45 min to rt. Upon 
reaching room temperature, water (12 mL) was added and stirring continued for 15 min. The 
reaction mixture was then washed successively with 5 % HCl (12 mL), saturated NaHCO3 (12 
mL) and brine (10 mL) using a separatory funnel. Collected organic layers were combined and 
dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude 
oil.25 Flash chromatography (20% EtOAc/hexanes) performed to get pure aldehyde 17 (941 mg, 
93%) as pale yellow oil. 
1H-NMR (500 MHz, CDCl3)  7.72 (d, 4H), 7.47-7.40 (m, 6H), 3.68 (t, J = 6.5 Hz, 2H), 3.68 (t, J 
= 6.5 Hz, 2H), 1.62-1.52 (m, 4H), 1.45-1.30 (m, 3H), 1.06 (s, 9H); 13C-NMR (500 MHz, CDCl3) 
 202.85, 135.8, 134.1,129.9, 127.9, 63.6, 43.8, 32.1, 32.5, 27.1, 19.5, 18.9; HRMS (ESI +, calcd 
for C21H30O2Si 340.1859 [M+H]+, found m/z 341.2015.  
 
(E)-7-((tert-Butyldiphenylsilyl)oxy)-hept-2-ene-1-ol(18): A solution of 5-((tert-
butyldiphenylsilyl)oxy)-pentanal (3.5 g, 10.47 mmol) and 
(carboxymethylene)triphenylphosphorane ( 3.64 g, 10.47 mmol) in anhydrous CH2Cl2  (35 ml) 
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was heated to reflux for 18 h. The reaction was cooled to room temperature, diluted with DI water 
and extracted with pentane (2 x 200 ml). Collected organic extract was dried over anyd. Na2SO4, 
filtered and concentrated under reduced pressure to afford crude yellow oil.25 Flash 
chromatography (15% EtOAc/hexanes) gave (E)-7-((tert-Butyldiphenylsilyl)oxy)-hept-2-enoic 
acid ethyl ester, 6 (3.14 g, 86% yield) as yellow oily compound. 
 1H-NMR (500 MHz, CDCl3)  7.74 (dt, J = 9.3,6.3 Hz, 4H), 7.49-7.42 (m, 6H), 7.03 (dt, J=  15.7, 
6.9 Hz, 1H), 5.89 (d, J = 15.6 Hz, 1H), 4.26 (q, J= 7.1 Hz, 2H), 3.72 (t, J= 5.6 Hz, 2H), 2.25 (q, 
J= 6.9 Hz, 2H ), 1.68-1.61 (m, 4H), 1.36 (t, 7.1 Hz, 3H), 1.12 (s, 9H); 13C-NMR (500 MHz, CDCl3) 
d 166.9, 149.4, 135.8, 134.2, 129.8, 121.6, 63.7, 60.3, 32.1, 27.1, 24.6, 19.5, 14.6; HRMS (ESI+, 
TFA-Na) calcd for C25H34NaO3Si 433.2175. [M+Na]+, found m/z 433.2161. 
 
To a solution of the corresponding -unsaturated ester, 6 (5.9 g, 14.87 mmol) in anhydrous 
CH2Cl2 (100 ml) was added DIBALH (1.02 M in hexanes, 30.6 ml, 31.2 mmol) at -78 
oC under 
N2. The mixture was then warmed to 0 
oC..  After stirring for 1 h at 0 oC, the reaction was cautiously 
quenched with cold MeOH at 0 oC, diluted with CH2Cl2 and celite (14.2 g) and Na2SO4.10H2O 
(14.2 g) were added to it. The mixture was allowed to warm to rt and stirred for 2 h, then filtered 
through a pad of celite and the filtrate was concentrated under reduced pressure. The residue was 
purified by flash column chromatography (30% EtOAc/hexanes) to give alcohol 18 (5.5 g, quant.) 
as a colorless oil.  
1H-NMR (500 MHz, CDCl3)  7.71 (dt, J = 1.4,6.5 Hz, 4H), 7.49-7.37 (m, 6H), 5.69 (m, 2H), 4.12 
(d, J= 5.6 Hz, 2H), 3.70 (t, J= 6.4 Hz, 2H), 2.07 (q, J= 7.1 Hz, 2H ), 1.63-1.46 (m, 4H), 1.09 (s, 
9H); 13C-NMR (500 MHz, CDCl3)  135.8, 134.3, 133.4, 129.8, 129.3, 127.9, 64.05, 32.2, 27.2, 
25.6, 19.5; HRMS (ESI+, TFA-Na) calcd for C23H32NaO2Si 391.2069. [M+Na]+, found m/z 
391.2134. 
 
(E)-7-((tetrahydro-2H-pyran-2-yl)oxy)hept-5-en-1-yl methanesulfonate (8): PPTS (214.76 mg, 
0.854 mmol) and DHP (7.8 ml, 85.4 mmol) were added to a solution of allyl alcohol 7 (3.15 g, 
8.54 mmol) in anhydrous CH2Cl2 (40 ml) at 0 
oC under N2. The reaction mixture was allowed to 
52 
 
stir for 6 h at 0 oC followed by quenching with H2O. The aqueous phase was extracted with EtOAc 
and combined organic extracts were washed with brine and dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography (15% 
EtOAc/hexanes) to afford the corresponding THP ether, 7 (3.5 g, 88% yield) as a colorless oil.15  
1H-NMR (500 MHz, CDCl3)  7.71 (d, J = 6.5, 4H), 7.47-7.41 (m, 6H), 5.72-5.69 (m, 1H), 5.63-
5.57 (m, 1H), 4.68 (m, 1H), 4.24-4.21 (m, 1H), 3.99-3.90 (m, 2H), 3.70 (t, J = 6.2 Hz, 2H), 3.55 
(m, 1H), 2.09 (m, 2H), 1.90 (m, 1H), 1.77 (m, 1H), 1.63 (m, 8H), 1.51 (m, 2H), 1.31 (m, 1H), 1.09 
(s, 9H); 13C-NMR (500 MHz, CDCl3)  135.8, 134.7, 134.3, 129.8, 126.5, 98.1, 68.1, 63.1, 64.0, 
62.5, 32.3, 30.9, 27.1, 25.6; HRMS (ESI+, TFA-Na) calcd for C28H40NaO3Si 475.2644 [M+Na]+, 
found m/z 475.2650. 
TBAF (9.2 ml from 1M solution in THF, 9.2 mmol) was added to a solution of the THP ether, 7 
(3.5 g, 7.74 mmol) in dry THF (55 ml) at rt under N2. The reaction mixture turned into orangish 
red in color and it was stirred for 4.5 h at rt. The reaction was quenched with H2O, and the aqueous 
phase was extracted with CH2Cl2. The combined organic extracts were washed with brine, 
following that it was dried over anhydrous Na2SO4 and concentrated in vacuo. Obtained yellowish 
orange crude residue was purified by flash column chromatography (50 % EtOAc/hexanes) to give 
corresponding TBDPS deprotected alcohol, 19 (1.45 g, 92 % yield) as colorless oil. Spectroscopic 
data matches with the reported data.15 
 1H-NMR (500 MHz, CDCl3)  5.74–5.67 (m, 1H), 5.62–5.57 (m, 1H), 4.63–4.60 (m, 1H), 4.18 
(ddd, J = 12.0, 5.7, 1.0 Hz, 1H), 3.93 (ddd, J = 12.0, 5.7, 1.0 Hz, 1H), 3.89–3.82 (m, 1H), 3.64 (t, 
J = 6.5 Hz, 2H), 3.52–3.48 (m, 1H), 2.12–2.04 (m, 2H), 1.86–1.43 (m, 10H); 13C-NMR (500 MHz, 
CDCl3)  134.5, 126.5, 97.9, 68.0, 62.8, 62.4, 32.4, 32.2, 30.8, 25.6, 25.4, 19.7; HRMS (FAB, m-
NBA) calcd for C12H22NaO3 273.1467 [M+Na]+, found m/z 273.1469. 
To a solution of 19 (1g, 4.66mmol) in CH2Cl2 (50ml) were added Et3N (1.3ml, 9.33mmol), 
Me3N.HCl (44.5mg, 0.47mmol) and MsCl (l, 6.99mmol) at 0 
oC under N2 atmosphere. The 
reaction mixture was allowed to warm to rt and stirred for 3h at rt. After that the reaction was 
quenched with H2O and the aqueous phase was extracted with CH2Cl2. The combined organic 
extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. Obtained 
yellowish orange residue was purified by flash column chromatography (40% EtOAc/hexanes) to 
afford the corresponding mesylate, 8 (1.35g, quant.) as a colorless oil. Spectroscopic data matches 
with the reported data.15  
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 1H-NMR (500MHz, CDCl3)  5.69–5.64 (m, 1H), 5.62–5.55 (m, 1H), 4.61–4.60 (m, 1H), 4.21 (t, 
J = 6.5Hz, 2H), 4.17 (ddd, J = 12.0, 5.3, 1.2Hz, 1H), 3.91 (ddd, J = 12.0, 5.3, 1.2Hz, 1H),3.88–
3.47 (m, 1H), 3.51–3.47 (m, 1H), 2.99 (s, 3H), 2.12–2.06 (m, 2H), 1.84– 1.46 (m, 10H); 13C-NMR 
(500MHz, CDCl3) 133.0, 127.0, 97.8, 69.8, 67.6, 62.2, 37.2, 31.5, 30.5, 28.5, 25.3, 24.7, 19.4; 
HRMS (ESI+, TFA-Na) calcd for C13H24NaO5S 315.1242 [M+Na], found m/z 315.1242. 
 
(E)-2-((7-Iodohept-2-en-1-yl)oxy)tetrahydro-2H-pyran (11): Following the same protocol as 
reported by Uchida M. et al.15 the OH was substituted with iodo group. Briefly, the mesyl ester, 
10(3.00g, 10.46mmol) was added to a solution of NaI (2.30g, 15.4mmol) in acetone (150ml) under 
N2 atmosphere. The reaction mixture was refluxed for 8.5h. After stirring at reflux for 8.5h, the 
reaction mixture was cooled to rt and the aqueous phase was extracted with EtOAc. Organic 
fractions were combined were dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (10% EtOAc/hexanes) to give 4 (2.0 g, 62% 
yield) as a yellow colored oil. Spectroscopic data matches with the reported data.15  
 1H-NMR (500MHz, CDCl3)  5.75–5.58 (m, 2H), 4.67 (dd, J = 4.3, 2.9Hz, 1H), 4.21 (ddd, J = 
12.0, 5.4, 1.0Hz, 1H), 3.93 (ddd, J = 12.0, 5.3, 1.2Hz, 1H), 3.92–3.88 (m, 1H), 3.57–3.52 (m, 1H), 
3.23 (t, J = 7.0Hz, 2H), 2.14–2.10 (m, 2H), 1.90–1.51 (m, 10H); 13C-NMR (500MHz, CDCl3)  
133.7, 127.1, 98.0, 67.9, 62.5, 33.2, 31.4, 30.9, 30.1, 25.7, 19.8, 7.0; HRMS (FAB, m-NBA): calcd 




(21). A solution of iodide 11 (1.0g, 3.08mmol) in anhydrous hexane (30 ml) was diluted with dry 
Et2O (12 ml) and cooled to -78 
oC. t-BuLi (1.7M in pentane, 4.2ml, 7.08mmol) was then added 
slowly (dropwise) at -78 oC under Ar. The solution turned milky white. After stirring for 15min at 
-78 oC, a solution of aldehyde 12 (753mg, 3.38mmol) in dry Et2O (8.0ml) was added slowly. The 
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reaction mixture was allowed to warm to 0 oC and stirred for 3h. The mixture was quenched with 
a saturated aqueous solution of NH4Cl and the aqueous phase was extracted with EtOAc (30ml x 
2). Organic extracts were combined, dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. Obtained crude oily residue was purified by flash column chromatography (20% 
EtOAc/hexanes) to afford diastereoisomeric mixture of 20 (1.34g, 96% yield) as a colorless oil 
which was used directly for next step without separating the distereomers. The TLC used to 
monitor the progress of the reaction was stained with blue stain (Cerric Ammonium Nitrate stain). 
Spectroscopic data matched perfectly with the reported values.15  
1H-NMR (500MHz, CDCl3)  7.26 (d, J = 8.8Hz, 2H), 6.88 (d, J = 8.8Hz, 2H), 5.75–5.68 (m, 
1H), 5.62–5.55 (m, 1H), 4.64 (dd, J = 3.5, 3.0Hz, 1H), 4.34 (s, 2H), 4.19 (ddd, J = 11.9, 5.6, 
1.1Hz, 1H), 3.92 (ddd, J = 11.9, 6.7, 0.8Hz, 1H), 3.88–3.82 (m, 1H), 3.80 (s, 3H), 3.68–3.64 (m, 
1H), 3.54–3.47 (m, 1H), 2.17–2.05 (m, 2H), 1.86–1.15 (m, 14H), 1.14 (s, 3H), 0.92 (t, J = 7.5Hz, 
3H); 13C-NMR (500MHz, CDCl3)  159.0, 134.9, 131.0, 128.9, 126.1, 113.8, 97.7, 80.1, 73.9, 
67.8, 62.8, 62.2, 55.2, 32.3, 30.8, 30.6, 29.6, 29.1, 26.5, 26.4, 25.4, 19.5, 17.6, 14.1, 7.34; HRMS 
(ESI+, TFA-Na) calcd for C25H40NaO5 443.2773 [M+Na]+, foundm/z 443.2754 
     A solution of the oxalyl chloride (1.42mL from 2M stock in dry DCM, 2.85mmol) in dry 
CH2Cl2 (15 mL) was cooled to -78 
oC under an atmosphere of Ar. A solution of dry DMSO (400 
L in 5mL DCM, 5.71 mmol), was added slowly until temperature is maintained below -65 oC. 
After stirring for 5 min, a solution of 14 (1.2 g, 2.85 mmol) in dry CH2Cl2 (10 mL) was added 
slowly, and resulting mixture was stirred slowly for 15 min, after which, Et3N (1.98 mL, 14.25 
mmol) was added slowly. After stirring the reaction for 10 additional min at -78 oC, the cooling 
bath was removed, and the reaction was allowed to warm for about 45 min to rt. Upon reaching 
room temperature, water (15 mL) was added and stirring continued for 15 min. The reaction 
mixture was then washed successively with 5 % HCl (15 mL), saturated NaHCO3 (15 mL) and 
brine (7 mL) using a separatory funnel. Collected organic layers were combined and dried with 
anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude oil.
25 Flash 
chromatography (15% EtOAc/hexanes) performed to get corresponding ketone 9 (1.1 g, 93% 
yield) as colorless oil. Spectroscopic data matches with the reported values.15 
1H-NMR (500MHz, CDCl3)  7.30 (d, J = 8.8Hz, 2H), 6.93 (d, J = 8.8Hz, 2H), 5.81–5.61 (m, 
1H), 5.61–5.49(m, 1H), 4.63–4.25 (m, 1H), 4.36 (d, J = 10.7Hz, 1H), 4.32 (d, J = 10.7Hz, 1H), 
4.22 (ddd, J = 12.0, 5.5, 1.1Hz, 1H), 3.96 (ddd, J = 12.0, 5.5, 1.1Hz, 1H), 3.92–3.87 (m, 1H) 3.84 
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(s, 3H), 3.76–3.55 (m, 1H), 2.68 (dt, J = 7.3, 3.5Hz, 2H), 2.10–2.05 (m, 2H), 1.93–1.44 (m, 10H), 
1.42–1.37 (m, 2H), 1.36 (s, 3H), 0.89 (t, J = 7.5Hz, 3H); 13C-NMR (500MHz, CDCl3) 215.1, 
159.3, 134.4, 130.9, 128.8, 126.6, 114.1, 98.0, 85.1, 68.1, 65.4, 62.5, 55.5, 37.0, 32.4, 30.9, 29.5, 
29.0, 25.7, 23.3, 20.1, 19.8, 8.1; HRMS (ESI+, TFA-Na) calcd for C25H38NaO5 441.2617 
[M+Na]+, found m/z 441.2614. 
PPTS (360 mg, 1.43 mmol) was added to a solution of the ketone 9 (600 mg, 1.43 mmol) in MeOH 
(15ml) at rt under N2. Followed by stirring at rt for 5 h, the reaction mixture was quenched with 
H2O and the aqueous phase was extracted with CH2Cl2. The combined organic extracts were 
washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (25% EtOAc/hexanes) to afford 
corresponding allyl alcohol 21 (475mg, 96%) as a colorless oil. Spectroscopic data matches to the 
reported values.15 
1H-NMR (500MHz, CDCl3)  7.30 (d, J = 8.8Hz, 2H), 6.93 (d, J = 8.8Hz, 2H), 5.70–5.57 (m, 
2H), 4.36 (d, J = 10.7Hz, 1H), 4.32 (d, J = 10.7Hz, 1H), 4.12-4.07 (m, 2H), 3.84 (s, 3H), 2.68 (dt, 
J = 7.3, 3.8Hz, 2H), 2.10-2.05 (m, 2H), 1.88–1.72 (m, 2H), 1.62–1.52 (m, 2H), 1.42–1.36 (m, 2H), 
1.36 (s, 3H), 0.87 (t, J = 7.5Hz, 3H); 13C-NMR (500MHz, CDCl3)  215.2, 159.3, 133.0, 130.9, 
129.5, 128.8, 114.1, 65.3, 63.9, 55.5, 37.0, 32.3, 29.5, 29.0, 23.2, 20.2, 8.1; HRMS (ESI+, TFA-




(22): Ti(OiPr)4 (728l, 2.4mmol) was added to a suspension of activated 4A˚ molecular sieves 
(320mg) and (+)-DET (422l, 2.4mmol) in dry CH2Cl2 (15.0ml) at -20 
oC under an atmosphere of 
Ar. After stirring for 0.5h, t-BuOOH (985.6l, 4.8mmol) was slowly added to the suspension at -
20 oC and the resulting mixture was continued to stir at -20 oC for 0.5h. A solution of 21 (800mg, 
2.4mmol) in CH2Cl2 (20ml) was then added dropwise to the reaction mixture at a constant rate and 
the mixture was stirred for 18h at -20 oC. The reaction was quenched with Me2S (250l, 3.35mmol) 
in 2mL DCM, diluted with CH2Cl2 (20mL) and treated with celite (2.62g) and Na2SO4.10H2O 
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(2.62g). The suspension was allowed to warm to rt and then stirred for 2h. The resulting mixture 
was filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The 
residue was purified by flash column chromatography (50% EtOAc/hexanes) to afford 10 (311mg, 
86%) as a colorless oil. Spectroscopic parameters match exactly with the reported values.15 1H-
NMR (500MHz, CDCl3) 7.29 (d, J = 8.8Hz, 2H), 6.91 (d, J = 8.8Hz, 2H), 4.36 (d, J = 10.7Hz, 
1H), 4.32 (d, J = 10.7Hz, 1H), 3.92–3.85 (m, 1H), 3.84 (s, 3H), 3.67–3.64 (m, 1H), 2.96–2.88 (m, 
2H), 2.69 (dt, J = 7.2, 2.6Hz, 2H), 1.89–1.77 (m, 2H), 1.75–1.58 (m, 4H), 1.50–1.41 (m, 2H), 1.35 
(s, 3H), 0.87 (t, J = 7.5Hz, 3H); 13C-NMR (500MHz, CDCl3)  214.9, 159.0, 130.7, 128.6, 113.8, 
84.9, 65.1, 61.7, 58.4, 55.8, 55.3, 36.8, 31.4, 29.2, 25.7, 23.1, 20.0, 7.91; HRMS (ESI+, TFA-Na) 
calcd for C20H30NaO5 373.1991 [M+Na]+, found m/z 373.1989. 
Following the protocol from the reported literature26 anhydrous ZnCl2 (2 mL, 1 M in Et2O, 2 mmol) 
and zinc powder (350 mg, 6.72 mmol) were added to a red solution of Cp2TiCl2 (1.26 g, 5.05 
mmol) in anhydrous THF (15 mL). The solution was stirred for 1h at room temperature until it 
turned green. Epoxide 10 (590 mg, 1.68 mmol) in anhydrous THF (5 mL) was then added to the 
resultant mixture. After stirring for 30 min at rt, the reaction was quenched with aqueous HCl (1.0 
M, 3 mL) and the mixture was extracted with Et2O (4 mL X 3). Collected Et2O fractions were 
combined and washed with water, 10% aq. NaHCO3, water and brine, dried over Na2SO4 and 
filtered and concentrated under reduced pressure. Obtained residue was purified using flash 
column chromatography on silica gel (25% EtOAc/hexane to 40% EtOAc/hexane) to obtain pure 
compound 22.  1H-NMR (500MHz, CDCl3)  7.27 (d, J = 8.8Hz, 2H), 6.89 (d, J = 8.8Hz, 2H), 
5.87-5.81 (m, 1H), 5.21 (ddd, J=17.2, 1.4, 1H), 5.10 (ddd, J=10.4, 1.4, 1H), 4.33 (d, J = 10.8Hz, 
1H), 4.29 (d, J = 10.8Hz, 1H), 4.14-4.06 ( m, 1H), 3.81 (s, 3H), 2.66 (dt, J = 7.3, 4.3Hz, 2H), 
1.84–1.70 (m, 2H), 1.59–1.34 (m, 6H), 1.33 (s, 3H), 0.84 (t, J = 7.5Hz, 3H); 13C-NMR (500MHz, 
CDCl3)  215.2, 159.0, 141.3, 128.9, 128.9, 114.9, 114.0, 113.8, 84.8, 73.2, 65.3, 55.5, 37.1, 36.8, 
29.4, 25.3, 23.5, 20.2, 8.1; HRMS (ESI+, TFA-Na) calcd for C20H30NaO4 357.2042 [M+Na]+, 





(3S,9R)-9-((4-Methoxybenzyl)oxy)-9-methyl-8-oxoundec-1-en-3-yl acrylate (23): Acryloyl 
chloride (87.1 l, 1.06 mmol), Et3N (300 l, 2.13 mmol) and DMAP (8.5 mg, 0.07 mmol, cat.) 
were added to a solution of the allyl alcohol 18 (230 mg, 0.71 mmol) in CH2Cl2 (10 ml) at 
oC under 
N2. The mixture was warmed to rt and stirred the reaction for 1 h at rt. After that it was quenched 
with H2O and the aqueous phase was extracted 3 times with CH2Cl2. Organic layers were combined 
and were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by 
flash column chromatography (80% hexanes/EtOAc) to afford acrylyl alkene 24 (230 mg, 90%) 
as a colorless oil. Spectroscopic data matches with the reported values.15  1H-NMR (500 MHz, 
CDCl3) 7.31 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.45 (dd J = 17.3, 1.5 Hz, 1H), 6.16 
(dd, J = 17.3, 10.4 Hz, 1H), 5.86–5.76 (m, 2H), 5.33–5.29 (m, 1H), 5.25 (ddd, J = 17.3, 9.3, 1.3 
Hz, 1H), 5.20 (ddd, J = 10.5, 5.9, 1.2 Hz, 1H), 4.36 (d, J = 10.7 Hz, 1H), 4.31 (d, J =10.7 Hz, 
1H), 3.84 (s, 3H), 2.68 (dt, J = 7.3, 3.9 Hz, 2H), 1.89–1.55 (m, 8H), 1.35 (s, 3H), 0.87 (t, J = 7.5 
Hz, 3H); 13C-NMR (500 MHz, CDCl3) 215.0, 165.7, 159.3, 136.5, 130.9, 130.9, 128.9, 128.9, 
117.0, 114.0, 113.8, 85.1, 75.0, 65.3, 55.5, 37.0, 34.3, 29.4, 25.0, 23.5, 20.2, 8.1; HRMS (ESI+, 
TFA-Na) calcd for C23H32NaO5 411.2147 [M+Na]+, found m/z 411.2136. 
 
 
 (4S,10R)-avenolide (13). 162 mg of DDQ (0.69mmol) was added to a solution of 23 (208mg, 
0.53mmol) in CH2Cl2: H2O (20:1, 5.2ml total) at rt under N2. After stirring for 1h at rt, the reaction 
was quenched with H2O and the aqueous phase was extracted with CH2Cl2. The combined organic 
extracts were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified 
by flash column chromatography (20-25% EtOAc/hexanes) to give the corresponding alcohol 20 
(125mg, quant.) as a colorless oil. All spectroscopic and optical density data matched exactly with 
the reported values.15 
             A solution of Grubbs second-generation catalyst (15 mg, 0.026 mmol) in CH2Cl2 (23ml) 
was added to a solution of the alcohol (100 mg, 0.37 mmol) in CH2Cl2 (12.5ml) at rt under N2. 
After 2h of stirring at 40oC, Quadrasil AP (1.25g) was added to the reaction mixture. The 
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suspension was stirred for additional 5 min at rt and then allowed to stand for 10 min. The mixture 
was filtered through a pad of celite and the filtrate was washed with H2O. The organic layers were 
dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified twice by flash 
column chromatography (50% EtOAC/hexanes) to afford 13 (28 mg, 78%) as a light browinsh 
oil. All optical density and spectroscopic values were matching to the reported values.15 
 []26D  (1, CHCl3) : +2.24; 
1H-NMR (500MHz, CDCl3)  7.49 (dd, J = 5.8, 1.5Hz, 1H), 6.17 (dd, 
J = 5.7, 2.0Hz, 1H), 5.10–5.03 (m, 1H), 3.80 (brs, 1H), 2.59–2.47 (m, 2H), 1.87-1.61 (m,6H), 
1.61–1.42 (m, 2H), 1.38 (s, 3H), 0.86 (t, J = 7.4Hz, 3H); 13C-NMR (500MHz, CDCl3) 214.4, 
173.2, 156.2, 121.9, 83.2, 79.1, 35.6, 33.2, 32.6, 25.4, 24.9, 23.4, 7.9; HRMS (FAB,m-NBA) calcd 



























































































































































































































































































































































































































Figure 3.2: (a) Organization of avenolide biosynthetic genes in s.avermitilis13 (b) Putative role of 






















Figure 3.3: (a) Avenolide mediated regulation of avermectin production, (b) Crystal structure of apo AvaR1 
transcriptional repressor. Both monomers are shown in different color in the homodimer. Ligand binding 












































Figure 3.5: (a) Avenolid-AvaR1 bound crystal structure; 1 ligand (shown in yellow ball model) bound per 


















Figure 3.6: (a) Zoomed into the active site and relative alignment of active site residues for avenolide-
AvaR1 binding, (b) Superposition of ligand bound (orange) and unbound (blue) structure to highlight 













Figure 3.7: (a) AvaR1 binding site in the upstream region of aco gene; (b) Crystals obtained with DNA 
Oligo Pal2-1 variant sequences; below the rightmost structure is the screenshot from COOT depicting the 


















Figure 3.8: (a) s.pheaochromogenes strain treated and untreated with 500nM avenolide (b) 
























Table 3.1: List of all the acoARE oligonucleotides tried for co-crystallization with AvaR1. Pal in 
the name denotes the palindromic sequences which have been designed using the first or the second 
half of the symmetric sequence and these are self-annealing. The first half of the sequence is 
complementary to the second half 
Target sequence (acoARE) : 5’-CTTGAAGACAAAACCGTCTAGTACGTATCTTTGA-3’ 
                                                     3’-GAACTTC TGTTTTGGCAGATCATGCATAGAAACT- 5’ 
aco_ARE_Oligo Sequence 
acoARE +1 5’-GAAGACAAAACCGTCTAGTACGTATCTTTGA-3’ 
3’-CTTC TGTTTTGGCAGATCATGCATAGAAACT-5’ 
acoARE +4 5’-CTTGAAGACAAAACCGTCTAGTACGTATCTTTGACCT-3’ 
3’-GAACTTC TGTTTTGGCAGATCATGCATAGAAACTGGA-5’ 
acoARE +5 5’-ACTTGAAGACAAAACCGTCTAGTACGTATCTTTG ACCTC-3’ 
3’-TGAACTTC TGTTTTGGCAGATCATGCATAGAAACTGGAG-5’ 
acoARE_pal1 5’-TTG AAG ACA AAA CCG TCT AGA CGG TTT TGT CTT CAA-3’ 
acoARE_pal2 5’-TCA AAG ATA CGT ACT AGT ACG TAT CTT TGA- 3’ 
acoARE_pal1 +1 each 5’-CTTG AAG ACA AAA CCG TCT AGA CGG TTT TGTCTTCAAG-3’ 
acoARE_pal2 +1 each 5’-GTCA AAG ATA CGT ACT AGT ACG TAT CTT TGAC-3’ 
acoARE_pal1-5' over A 5’-ATTG AAG ACA AAA CCG TCT AGA CGG TTT TGT CTT CAA-3’ 
acoARE_pal2 5' over A 5’-ATCA AAG ATA CGT ACT AGT ACG TAT CTT TGA-3’ 
acoARE_pal1-2 each 5’- G AAG ACA AAA CCG TCT AGA CGG TTT TGT CTT C-3’ 
acoARE_pal2-1 each 5’- CA AAG ATA CGT ACT AGT ACG TAT CTT TG- 3’ 
acoARE_pal2-2 each 5’- A AAG ATA CGT ACT AGT ACG TAT CTT T- 3’ 
acoARE_pal2-1-3’G 5’- CA AAG ATA CGT ACT AGT ACG TAT CTT T- 3’ 
acoARE_pal2-1each-5’C 5’- CCA AAG ATA CGT ACT AGT ACG TAT CTT TG- 3’ 
acoARE_pal2-1each-3’G 5’- CA AAG ATA CGT ACT AGT ACG TAT CTT TGG- 3’ 
acoARE_pal2 -1e+GCpair 5’- GCA AAG ATA CGT ACT AGT ACG TAT CTT TGC- 3’ 
acoARE_Pal2-3each 5’-AAG ATA CGT ACT AGT ACG TAT CTT- 3’ 
acoARE_Pal2-1-5'CG 5’-CGAAG ATA CGT ACT AGT ACG TAT CTT CG- 3’ 
acoARE_Pal2-1-5'GC 5’- GCAAG ATA CGT ACT AGT ACG TAT CTT GC- 3’ 
acoARE_Pal2-1-5'TA 5’- TAAAG ATA CGT ACT AGT ACG TAT CTT TA- 3’ 
acoARE_Pal2-1-5'AT 5’-ATAAG ATA CGT ACT AGT ACG TAT CTT AT- 3’ 
acoARE_Pal2-1-5'GC-Mid G 5’- GCAAG ATA CGT ACTG AGT ACG TAT CTT GC- 3’ 
acoARE_Pal2-1-5'GC-Mid 
GC 




Table 3.2:  List of identified Streptomyces strains with homology to aco and cyp genes involved 










Table 3.3: Crystallographic refinement parameters 
 AvaR1-avenolide    
Data collection    
Space Group P1211   
Wavelength (Å)                             0.9832   
Cell: a, b, c (Å) 44.5, 233.1, 88.2   
Resolution (Å)1 25-2.0 (2.05-2.00)   
Completeness (%) 99.9 (98.9)   
Refinement    
Resolution (Å) 25-2.0   
No. reflections 113,371   
Rwork / Rfree
2 23.89/27.15   
Number of atoms    
Protein   13242   
B-factors    
Protein  24.7   
R.m.s. deviations    
Bond lengths (Å) 0.010   
Bond Angles (o) 1.503   
 
Ramachandran Plot 
   
Favored, outliers (%) 99.1, 0.0   
    
1Highest resolution shell is shown in parenthesis. 
2R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% 
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